document incorporate reference portion proxy statement registrant annual meeting stockholder hold file day conclusion registrant fiscal year end december incorporate reference iii annual report bristolmyer squibb company index december item business acquisition divestiture product intellectual property product exclusivity research development alliance marketing distribution customer competition pricing price constraint market access government regulation source availability raw material manufacturing quality assurance environmental regulation employee foreign operation bristolmyer squibb website item risk factor item unresolved staff comment item property item legal proceeding item safety disclosure executive officer registrant item market registrant common stock stockholder matter item select financial datum item management discussion analysis financial condition result operation item quantitative qualitative disclosure market risk item financial statement supplementary datum consolidate statement earning comprehensive income consolidate balance sheet consolidate statement cash flow note financial statement item change disagreement accountant account financial disclosure item control procedure item information iii item director executive officer registrant item executive compensation item security ownership certain beneficial owner management relate stockholder matter item certain relationship relate transaction item auditor fee item exhibit financial statement schedule item summary signature summary abbreviate term exhibit index indicate brand name product trademark own bms specific trademark ownership information include exhibit indexpart item business general bristolmyers squibb company incorporate law state delaware august bristolmyer company successor new york business start bristolmyer company change bristolmyer squibb company result merger engage discovery development licensing manufacturing marketing distribution sale biopharmaceutical product global basis refer summary abbreviate term end term document operate segmentbiopharmaceutical additional information business segment refer item financial statementsnote business segment information compete worldwide researchbase drug company small research company generic drug manufacturer product sell worldwide primarily wholesaler retail pharmacy hospital government entity medical profession manufacture product puerto rico foreign country revenue come product follow therapeutic class oncology cardiovascular immunoscience virology include hiv infection percentage revenue significant regioncountry follow year end december dollar millions united states europe japan total revenue acquisition divestiture acquisition year include ifm cormorant padlock cardioxyl flexus ipierian enter license collaboration arrangement divestiture year include small molecule manufacturing operation sword ireland certain otc brand investigational hiv medicine business erbitux north america certain mature otc brand business diabete business outlicense genetically define disease investigational compound transaction continue allow focus resource growth opportunity drive great longterm value product intellectual property product exclusivity pharmaceutical product include chemicallysynthesize small molecule drug product produce biological process call biologic small molecule drug typically administer orally form pill tablet drug delivery mechanism biologic typically administer patient injection intravenous infusion product summary include approve indication information alliance arrangement product refer alliance item financial statementsnote alliance opdivo opdivo biological product fully human monoclonal antibody bind nkt cell opdivo receive approval anticancer indication include bladder blood colon head neck kidney liver lung melanoma stomach opdivoyervoy regimen approve multiple market treatment melanoma ongoing potentially registrational study opdivo tumor type disease area monotherapy combination yervoy anticancer agent eliquis eliquis oral factor inhibitor target stroke prevention atrial fibrillation prevention treatment vte disorder orencia orencia biological product fusion protein novel immunosuppressive activity target initially adult patient moderately severely active psa inadequate response certain currently available treatment orencia indicate certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis sprycel sprycel multitargete tyrosine kinase inhibitor approve firstline treatment adult philadelphia chromosomepositive cml chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase chronic myeloid leukemia resistance intolerance prior therapy include gleevec imatinib mesylate treatment child philadelphia chromosome positive cml chronic phase yervoy yervoy biological product monoclonal antibody treatment adult pediatric patient unresectable metastatic melanoma adjuvant treatment patient melanoma undergone complete resection empliciti empliciti biological product humanize monoclonal antibody treatment multiple myeloma baraclude baraclude potent selective inhibitor hepatitis virus sustiva franchise sustiva franchise include sustiva nonnucleoside reverse transcriptase inhibitor treatment hiv bulk efavirenz include combination therapy atripla reyataz franchise reyataz franchise include reyataz protease inhibitor treatment hiv combination therapy evotaz combine reyataz gilead tybost hepatitis franchise daklinza daclatasvir dcv oral small molecule nsa replication complex inhibitor treatment hcv sunvepra asunaprevir asv oral small molecule protease inhibitor treatment hcv dual regimen dcvasv japan china license number patent foreign country primarily cover product develop brand name trademark product consider overall protection patent trademark license intellectual property right material value act protect right infringement pharmaceutical industry majority innovative product commercial value usually realize period product market exclusivity product market exclusivity generally determine form intellectual property patent right hold innovator company regulatory form exclusivity innovative drug entitle patent key determinant market exclusivity brand pharmaceutical patent provide innovator right exclude practice invention relate medicine patent cover thing active ingredient use drug product pharmaceutical formulation drug delivery mechanism process intermediate useful manufacture product protection individual product extend vary period accordance expiration date patent country protection afford vary country country depend type patent scope coverage availability meaningful legal remedy country market exclusivity influence regulatory data protection exclusivity right develop country provide certain nonpatent incentive development medicine example japan certain country regulatory data protection exclusivity right offer incentive research medicine rare disease orphan drug medicine useful treat pediatric patient incentive provide market exclusivity period product expire patent term japan provide regulatory datum protection period time approval new drug regulatory agency rely innovators data approve competitor generic copy certain market patent protection form market exclusivity expire regulatory data protection particular importance regulatory form exclusivity prevent competitor gain regulatory approval prior expiration regulatory data protection exclusivity basis competitor safety efficacy datum drug drug identical market innovator patent right form exclusivity expire generic version medicine approve market substantial rapid decline sale original innovative product discussion impact generic competition business refer generic competition specific aspect law govern market exclusivity datum regulatory protection pharmaceutical vary country country follow summarize key exclusivity rule market represent significant sale united state key product protect patent vary term depend type patent filing date significant portion product patent life lose time take innovative company develop obtain regulatory approval new drug compensation lose patent term regulatory review period innovator depend number factor apply government restore lose patent term extend expiration date patent maximum term year provide extension cause patent effect year date drug approval company seek market innovative pharmaceutical submit complete set safety efficacy datum fda innovative pharmaceutical chemical product company file nda medicine biological product bla file type application file affect regulatory data protection exclusivity right chemical product competitor seek launch generic substitute chemical innovative drug file anda fda anda generic manufacturer need demonstrate bioequivalence generic substitute approve nda drug anda rely safety efficacy datum previously file innovator nda innovator company require list certain patent cover medicine fda commonly know orange book absent successful patent challenge fda approve anda innovators list patent expire innovator market product year generic manufacturer file anda allege patent list orange book innovators nda invalid infringe allegation commonly know paragraph certification innovator decide file patent infringement suit generic manufacturer time time anda include paragraph certification file respect certain product evaluate andas casebycase basis warrant file suit generic manufacturer protect patent right addition patent protection certain innovative pharmaceutical product receive period regulatory exclusivity nda designate orphan drug receive seven year exclusivity orphan indication time period nda andas drug product approve orphan use company earn month additional exclusivity drug specific clinical study conduct write request fda study use medicine treat pediatric patient submission fda prior loss basic exclusivity medicine approve nda receive type regulatory data protection innovative chemical pharmaceutical product entitle year regulatory data protection fda approve generic substitute innovators patent challenge describe generic manufacturer file anda fourth year fiveyear regulatory datum protection period pharmaceutical drug product contain active ingredient previously approve nda approve new formulation drug new indication basis new clinical study receive year regulatory data protection formulation indication biologic product healthcare legislation enact create approval pathway biosimilar version innovative biological product previously exist prior time innovative biologic essentially unlimited regulatory exclusivity new regulatory mechanism fda approve product similar generic copy innovative biologic basis extensive datum require bla innovator market product year manufacturer file application approval biosimilar version innovator product application approval biosimilar file year approval innovator product qualify innovative biological product receive year regulatory exclusivity mean fda approve biosimilar version year innovative biological product approve fda law provide mechanism innovator enforce patent protect innovative biological product biosimilar applicant challenge patent patent litigation begin early year innovative biological product approve fda increase likelihood generic biosimilar challenge innovators intellectual property increase risk loss innovator market exclusivity generic company increasingly seek challenge innovator basic patent cover major pharmaceutical product second statutory regulatory provision limit ability innovator company prevent generic biosimilar drug approve launch patent litigation ongoing result development possible predict length market exclusivity particular product certainty base solely expiration relevant patent current form regulatory exclusivity european union patent pharmaceutical product generally enforceable extended compensate patent term lose regulatory review process extension grant countrybycountry basis primary route use obtain marketing authorization pharmaceutical product centralized procedure procedure compulsory certain pharmaceutical product particular biotechnological process available certain new chemical compound product company seek market innovative pharmaceutical product centralized procedure file complete set safety datum efficacy datum maa ema ema evaluate maa provide recommendation approve deny maa possible new chemical product obtain marketing authorization mutual recognition procedure application single member state member state approve pharmaceutical product national procedure applicant submit approval mutual recognition procedure member state obtain marketing authorization approval company obtain pricing reimbursement pharmaceutical product typically subject member state law certain country process place simultaneously product market country process complete company market new product pricing reimbursement procedure month year complete product marketing authorization file octobernovember subject regime year innovator receive community authorization medicinal product generic company file marketing authorization application product health authority market authorization application approve generic company commercialize product year elapse initial marketing authorization grant innovator possible extension year available innovator year marketing authorization obtain additional indication significant clinical benefit comparison exist treatment product file prior octobernovember year period datum protection centralize procedure period year mutual recognition procedure depend member state contrast patent list regulatory authority generic version pharmaceutical product approve data protection expire regardless innovator hold patent cover drug possible innovator seek enforce patent generic competitor market product european patent system opposition procedure generic manufacturer challenge validity patent cover innovator product month grant general law treat chemicallysynthesize drug biologicallyderive drug respect intellectual property datum protection addition relevant legislation annexe relate biologic medicinal product ema issue guideline outline additional information provide biosimilar product know generic biologic order review application marketing approval japan japan medicines new chemical entity generally afford year datum exclusivity approve indication dosage patent pharmaceutical product enforceable generic copy receive regulatory approval datum exclusivity patent expiration patent japan extended compensate patent term lose regulatory review process general japanese law treat chemicallysynthesize biologicallyderive drug respect intellectual property market exclusivity rest world country outside japan wide variety legal system respect intellectual property market exclusivity pharmaceutical develop country utilize system similar develop country adopt patent law andor regulatory exclusivity law develop country formally adopt law order comply wto commitment take step implement law meaningful way enforcement wto action long process government assurance outcome assess likely future market exclusivity innovative drug develop country account formal legal right political factor follow chart show key product year early basic exclusivity loss patent right datum exclusivity occur currently estimate occur japan sell pharmaceutical product country datum provide country bycountry basis individual country revenue significant outside japan instance basic exclusivity loss date list expiration date patent claim active ingredient drug method drug approve indication approve indication instance basic exclusivity loss date list chart expiration date datum exclusivity period situation datum exclusivity patent protection competitor seek regulatory approval submit clinical study datum obtain marketing approval prior expiration datum exclusivity estimate market exclusivity period product purpose business planning length market exclusivity product impossible predict certainty complex interaction patent regulatory form exclusivity inherent uncertainty patent litigation assurance particular product enjoy market exclusivity period time appear estimate exclusivity limited estimate total revenue product estimate loe dollar million japan prioritize brand opdivo nivolumab eliquis apixaban orencia abatacept sprycel dasatinib yervoy ipilimumab empliciti elotuzumab establish brand baraclude entecavir sustiva efavirenz franchise reyataz atazanavir sulfate franchise hepatitis franchise note estimate year basic loe table includes grant extension patent term restoration ptr andor month pediatric extension obtain laterexpire patent cover particular form composition method manufacturing method drug result favorable market position product product exclusivity predict assure regulatory data protection rdp obtain describe detail product intellectual property product exclusivity section reference include member states year end december basic patent application file current member state list product instance date basic exclusivity loss different member states currently market product country region indicate february epo board appeal revoke composition matter com patent february epo board appeal reverse remand invalidity decision use dasatinib treat cml epos opposition division revoke october refer item financial statementsnote legal proceeding contingency information opdivo bms jointly own patent ono cover nivolumab com expire ptrs file grant expire com patent cover nivolumab japan expire include grant ptr eliquis loe base com patent expire japan include grant ptr bms receive paragraph certification twentyfive anda filer initiate hatch waxman patent litigation april bms settle anda filer country grant ptr com patent expire orencia com patent include ptr expire method use patent cover indication expire japan loe base rdp exclusivity expire formulation additional patent direct abatacept expire bms aware orencia biosimilar market japan sprycel com patent include ptr expire june bms enter settlement agreement apotex patent infringement suit cover monohydrate form dasatinib apotex launch generic dasatinib monohydrate anda product september early certain circumstance japan com patent expire rdp expire information country footnote yervoy japan loe base com patent expire include grant ptrs com patent expire include ptr grant country country ptr grant com patent expire rdp expire empliciti loe period japan base rdp exclusivity ptrs file japan grant expire bms commercialization agreement abbvie empliciti abbvie own com patent covering elotuzumab expire japan exclude potential ptrs information arrangement abbvie refer alliance item financial statementsnote alliance sustiva franchise exclusivity period relate sustiva brand include exclusivity relate combination therapy loe efavirenz occur december reyataz market exclusivity project expire com patent include ptr expire expire hepatitis franchise relate product include daclatasvir daklinza brand loe base com patent expiry pende ptr grant expiry europe loe base com patent expiry ptr grant country expire japan com patent expire include grant ptr research development critical longterm competitiveness concentrate effort follow disease area significant unmet medical need oncology include immunoscience priority lupus inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priority lung ipf liver nash continue analyze selectively pursue promising lead area addition discover develop new molecular entity look way expand value exist product new indication formulation provide additional benefit patient order new drug reach market industry practice government regulation foreign country provide determination drug effectiveness safety preclinical test control clinical evaluation clinical development potential new drug typically include phase phase phase iii clinical study design specifically support new drug application particular indication assume study successful phase clinical study involve small number healthy volunteer patient suffer indicate disease test safety proper dosing phase clinical study involve large patient population investigate effect efficacy optimal dosage drug candidate phase iii clinical study conduct confirm phase result significantly large patient population long term provide reliable conclusive datum safety efficacy drug candidate regulatory approval typically base result phase iii clinical study times approval grant base datum early study consider registrational study significant program program include investigational compound phases iii development initial indication market product development additional indication formulation expand currently market product particularly opdivo combination yervoy agent secondline therapy new indication substantial portion program strategy drug development time consume expensive risky process typically take fourteen year approximately half year spend phase iii latestage development average chemical compound discover pharmaceutical industry researcher prove medically effective safe approve medicine drug candidate fail stage process latestage product candidate fail receive regulatory approval accord kmr group base industry success rate approximately compound enter phase development fail achieve regulatory approval compound enter phase development failure rate approximately approximately fail phase iii development total expense include cost discovery research preclinical development early latestage clinical development drug formulation postcommercialization medical support market product proportionate allocation enterprisewide cost license acquire asset expense billion billion billion include license asset acquisition charge approximately billion million billion respectively end employ approximately people relate support activity include substantial number physician scientist hold graduate postgraduate degree higherskille technical personnel manage program portfolio basis invest resource stage early discovery latestage development continually evaluate portfolio asset ensure appropriate balance earlystage latestage program support future growth company spend latestage development program represent approximately annual expense year opdivo individual investigational compound market product represent expense year operating model evolution geographic footprint significantly transform foster speed innovation future transformation involve closing hopewell new jersey wallingford connecticut site accompany additional investment expansion open example expand lawrenceville new jersey redwood city california site plan open new facility cambridge massachusetts supplement internal drug discovery development program alliance collaborative agreement help bring new molecular agent capability platform pipeline management continue emphasize leadership innovation productivity quality strategy success activity list investigational compound clinical study approve potential indication market product relate therapeutic area january list compound ultimately market product depend result clinical study competitive landscape potential product market reimbursement decision payer manufacturing process necessary produce potential product commercial scale factor assurance seek regulatory approval compound approval sought obtain assurance compound get approve commercially successful stage development determine intellectual property issue patent protection available investigational compound february follow potential registrational study readout opdivo anticipate tumor study detail tumor study detail opdivo yervoy line opdivo yervoy line nonsmall cell lung opdivo chemo line head neck cancer opdivo yervoy line cancer cmla opdivo yervoy chemo line opdivo line hepatocellular small cell lung cancer opdivo yervoy line maintenance opdivo line carcinoma gastric cancer opdivo yervoy chemo line key phase phase iii alliance enter alliance party transfer right develop manufacture market andor sell pharmaceutical product alliance include license codevelopment comarketing copromotion arrangement joint venture alliance involve share research development cost risk incur research development expense compound lead revenuegenerate product reduce profitability alliance product generally low profit alliance product share alliance partner actively pursue arrangement view alliance important complement discovery development commercialization activity alliance arrangement contain customary early termination provision follow material breach bankruptcy product safety concern notice require early termination generally range immediately notice day receipt notice termination immediately notice generally available party file voluntary bankruptcy petition material safety issue arise product medical riskbenefit incompatible welfare patient continue develop commercialize product termination notice period generally available involuntary bankruptcy petition file dismiss material breach party occur cure alliance agreement permit terminate cause typically exercisable substantial advance write notice exercisable specify period time elapse alliance agreement sign alliance typically contain provision provide party right terminate alliance typically retain right party product intellectual property alliance terminate loss right product market sell pursuant alliance material result operation cash flow material financial condition liquidity customary pharmaceutical industry term alliance generally coextensive exclusivity period vary country bycountry basis significant alliance currently market product investigational compound describe refer item financial statementsnote alliance additional information alliance agreement alliance agreement pfizer bms pfizer jointly develop commercialize eliquis bms recognize net product sale market worldwide profit loss share equally certain country pfizer commercialize eliquis pay bms salesbased fee otsuka bms otsuka jointly promote sprycel bms recognize net product sale salesbase fee pay otsuka ono bms exclusive right develop manufacture commercialize opdivo worldwide japan south korea taiwan bms recognize net product sale pay ono royalty north america applicable territory exclude country list subject customary adjustment bms ono jointly develop commercialize opdivo yervoy bms investigational compound japan south korea taiwan bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote assign customer account bms responsible product supply copromotion fee pay sale partys assign customer abbvie bms abbvie jointly develop empliciti abbvie fund global development cost bms solely responsible supply distribution sale marketing activity recognize net product sale abbvie share profit loss pay tiere royalty outside gilead bms gilead form joint venture develop commercialize atripla canada europe bms recognize alliance revenue bulk efavirenz component atripla sale atripla thirdparty customer december gilead terminate bms participation joint venture include canada market follow launch generic version sustiva bm receive sale base fee gilead net sale atripla license arrangement inlicense outlicense arrangement active participation party include obtain acquisition typically entitle receive obligate pay contingent milestone payment royaltie product commercialize marketing distribution customer promote appropriate use product directly healthcare professional organization doctor nurse practitioner physician assistant pharmacist technologist hospital pbms mco provide information appropriate use product consumer directtoconsumer print radio television digital advertising promotion addition sponsor general advertising educate public innovative medical research corporate mission discussion regulation promotion marketing pharmaceutical refer government regulation field sale medical organization explain risk benefit approve use product medical professional work gain access product formulary reimbursement plan list recommend approve medicine product include medicare plan provide information clinical profile product marketing sale prescription pharmaceutical limit approve use particular product continue develop scientific datum information potential additional use product provide information scientific exchange scientific congress share information product appropriate way include development publication response unsolicited inquiry doctor medical professional mcos operation include marketing sale organization product marketing organization support sale force responsible sell product market organization focus certain class customer manage care entity certain type marketing tool digital consumer communication sale force focus communicate information new approve product use approve use establish product promotion physician increasingly target physician specialist treat patient need medicine product sell principally wholesaler specialty distributor less extent directly distributor retailer hospital clinic government agency pharmacy refer item financial statementsnote business segment information gross revenue large pharmaceutical wholesaler percentage global gross revenue business dsas substantially direct wholesaler distributor customer allow monitor wholesaler distributor inventory level require wholesaler distributor maintain inventory level month demand dsa include large wholesaler expire december enter letter agreement large wholesaler specialty distributor affiliate extend current agreement march enter final agreement december prior expiration letter agreement nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report reliably gather report inventory level customer number country outside contract distributor support certain product service provide distributor vary market include distribution logistic regulatory pharmacovigilance andor sale advertising promotion sale distributorbase country represent approximately company total revenue competition market compete generally broad base highly competitive compete worldwide researchbase drug company small research company limit therapeutic focus generic drug manufacturer important competitive factor include product efficacy safety ease use price demonstrate costeffectiveness marketing effectiveness product label customer service new product process sale product impact new study indicate competitor product safe effective treat disease particular form disease product revenue impact additional labeling requirement relate safety convenience impose product fda similar regulatory agency different country competitor introduce new product process therapeutic cost advantage product subject progressive price reduction decrease volume sale advancement treat cancer therapy continue evolve rapid pace product particularly opdivo operate highly competitive marketplace addition compete market share product approve indication lung cancer melanoma face increase competition exist compete product receive fda approval additional indication new agent receive fda approval enter market furthermore therapy combine different product product exist chemotherapy target therapy treatment investigate potential expand approval anticipate product continue experience intense competition competitive challenge face generic pharmaceutical manufacturer regulatory approval process exempt generic costly timeconsuming clinical study demonstrate safety efficacy allow generic manufacturer rely safety efficacy innovator product result generic pharmaceutical manufacturer typically invest far researchbase pharmaceutical company price product significantly lower brand product accordingly brand product lose market exclusivity normally face intense price competition generic form product expiration loss market exclusivity product lose major portion product revenue short period time expiration exclusivity rate revenue decline product vary country general decline market rapid develop country observe rapid decline number country decline develop country tend rapid develop country rate revenue decline expiration exclusivity historically influence product characteristic example drug large patient population prescribed key primary care physician tend experience rapid decline drug specialized area medicine oncology drug complex manufacture sterile injectable product usually experience slow decline simple manufacture certain country outside patent protection weak nonexistent compete generic version shortly launch innovative product addition generic pharmaceutical company introduce generic product exclusivity expire resolution relate patent litigation information market exclusivity refer product intellectual property product exclusivity believe longterm competitive position depend success discover develop innovative costeffective product serve unmet medical need ability manufacture product efficiently market effectively highly competitive environment pricing price constraint market access medicine price base number factor include value scientific innovation patient society context overall health care spend economic factor impact health care system ability provide appropriate sustainable access necessity sustain investment innovation platform address unmet medical need central price clinical value innovation bring market current landscape alternative treatment option goal ensure appropriate patient access innovation sustain investment creative platform continue explore new pricing approach ensure patient access medicine enhance patient access medicine priority focus offer creative tiere pricing voluntary licensing reimbursement support patient assistance program optimize access protect innovation advocate sustainable healthcare policy infrastructure leverage advocacypayer input utilize partnership appropriate improve access care supportive service vulnerable patient partnership demonstration project monitor new state law law recently enact california vermont nevada new york focus drug pricing transparency andor limit state spend drug law create new constraint ability set price andor impact market access certain state growth mcos optum uhc silver script cvs express script esi major factor healthcare marketplace half population participate version manage care mco include medical insurance company medical plan administrator health maintenance organization medicare prescription drug plan alliance hospital physician physician organization organization consolidate few large entity enhance purchasing strength importance successfully compete business mcos demonstrate product offer medical benefit cost advantage compare form care new product introduce compete product market product later develop competitor note generic drug exempt costly timeconsuming clinical study demonstrate safety efficacy lower cost brandname drug mcos focus primarily immediate cost drug favor generic reason government encourage use generic alternative brandname drug healthcare program law generally allow case require pharmacist substitute generic drug rate government procedure essentially equivalent brandname drug substitution prescribe physician expressly forbid exclusion product formulary lead sharply reduce usage mco patient population consequently pharmaceutical company compete aggressively product include possible company compete inclusion base unique feature product great efficacy well patient ease use few effect low overall cost therapy important factor product demonstrate few therapeutic advantage compete inclusion base primarily price generally universally successful major product include mco formulary market outside operate environment governmentmandate costcontainment program market significant portion fund healthcare service determination pricing reimbursement pharmaceutical product subject government control result product face restrict access public private payer subject assessment comparative value effectiveness competitive product government place restriction physician prescription level patient reimbursement emphasize great use generic drug andor enact acrosstheboard price cut method cost control countries example government regulate price new product launch direct price control international price comparison control profit andor reference pricing market germany government set pricing restriction launch pricing freedom subsequently limit company face significant delay market access new product mainly france spain italy belgium year elapse new medicine available national market additionally member states regularly impose new additional cost containment measure pharmaceutical volume discount cost cap cost sharing increase excess prior year cost individual product aggregate market level spend outcomebase pricing scheme free product portion expect therapy period recent year italy example impose mandatory price decrease existence price differential different national pricing reimbursement law lead significant parallel trade flow government regulation pharmaceutical industry subject extensive global regulation regional country state local agency federal food drug cosmetic act federal statute regulation state statute regulation include newly enact state law regulate drug price transparency drug spending law regulation foreign government govern vary degree test approval production labeling distribution postmarket surveillance advertising dissemination information promotion product lengthy process laboratory clinical testing datum analysis manufacture development regulatory review necessary require governmental approval extremely costly significantly delay product introduction give market promotion marketing manufacturing distribution pharmaceutical product extensively regulate major world market addition operation subject complex federal state local foreign environmental occupational safety law regulation anticipate law regulation affect manufacture sale current product introduction new product continue require substantial scientific technical effort time expense significant capital investment fda particular importance jurisdiction virtually activity impose requirement cover testing safety effectiveness manufacturing labeling marketing advertising postmarkete surveillance product case fda requirement increase time money necessary develop new product bring market fda mandate drug manufacture package label conformity cgmp establish fda comply cgmp regulation manufacturer continue expend time money effort production recordkeeping quality control ensure product meet applicable specification requirement ensure product safety efficacy fda periodically inspect drug manufacturing facility ensure compliance applicable cgmp requirement failure comply statutory regulatory requirement subject possible legal regulatory action suspension manufacturing seizure product voluntary recall product adverse experience use product report fda result imposition market restriction label change product removal product approval withdraw compliance regulatory requirement maintain problem concern safety efficacy occur follow approval federal government extensive enforcement power activitie pharmaceutical manufacturer include authority withdraw delay product approval commence action seize prohibit sale unapproved noncomplye product halt manufacture operation compliance cgmp impose seek injunction voluntary recall civil monetary criminal penalty restriction prohibition sale withdrawal approval product market materially adversely affect business financial condition result operation cash flow marketing authorization product subject revocation applicable governmental agency addition modification enhancement approve product change manufacturing location circumstance subject additional fda approval receive subject lengthy application process distribution pharmaceutical product subject pdma federal food drug cosmetic act regulate activity federal state level pdma implement regulation state permit require registration manufacturer distributor provide pharmaceutical manufacturer distributor place business state state permit adopt regulation limit distribution product sample license practitioner pdma impose extensive licensing personnel recordkeeping packaging quantity labeling product handle facility storage security requirement intend prevent sale pharmaceutical product sample product diversion fda amendment act impose additional obligation pharmaceutical company delegate enforcement authority fda area drug safety key element legislation fda authority require company conduct postmarkete safety study drug impose certain safety relate drug labeling change mandate risk mitigation measure education healthcare provider restrict distribution medicine require company publicly disclose datum clinical study prereview television advertisement marketing practice pharmaceutical manufacturer subject federal state healthcare law protect integrity government healthcare program oig oversee compliance applicable federal law connection payment product government fund program primarily medicaid medicare law include federal antikickback statute criminalize offer value induce recommendation order purchase product service reimburse government healthcare program oig issue series guidance segment healthcare industry include compliance program guidance pharmaceutical manufacturer include recommendation pharmaceutical manufacturer minimum adhere phrma code voluntary industry code marketing practice subscribe phrma code implement compliance program address requirement set forth guidance compliance healthcare law failure comply healthcare law subject administrative legal proceeding include action federal state government agency action result imposition civil criminal sanction include fine penalty injunctive remedy impact materially adversely affect business financial condition result operation cash flow subject jurisdiction federal state regulatory enforcement department agency federal trade commission department justice department health human service license drug enforcement agency procure produce control substance subject possible administrative legal proceeding action organization action result imposition civil criminal sanction include fine penalty injunctive administrative remedy healthcare industry subject governmentimposed regulation authorize price price control continue impact total revenue participate state government medicaid program certain qualify federal state government program discount rebate provide participate state local government entity participate government program specify discount certain government entity significant department defense department veterans affair entity receive minimum discount base define nonfederal average manufacturer price purchase result patient protection affordable care act reconciliation bill contain package change healthcare bill continue experience additional financial cost certain change business example minimum rebate medicaid drug sale increase medicaid rebate extend drug riskbase medicaid manage care plan addition extend discount certain critical access hospital cancer hospital cover entity require expansion drug pricing program public health service act require provide discount brandname drug patient fall medicare coverage gap refer donut hole pay annual nontaxdeductible fee federal government base allocation market share brand drug sale certain government program include medicare medicaid department veterans affairs department defense tricare annual fee impose pharmaceutical manufacturer billion fee billion decrease billion activity outside subject regulatory requirement govern testing approval safety effectiveness manufacturing labeling marketing product regulatory requirement vary country country fda approval obtain product approval product comparable regulatory authority country outside case obtain prior marketing product country approval process rigorous country country time require approval long shorter require approval country assure product approve country discussion rebate program refer item management discussion analysis financial condition result operation gtn adjustment critical accounting policy source availability raw material general purchase raw material supply require production product open market product purchase raw material supply source source available single source approve source available require obtain raw material supply particular source attempt possible mitigate raw material supply risk inventory management alternative source strategy discussion source refer manufacture quality assurance discussion particular product manufacture quality assurance operate manage manufacturing network manner permit improve efficiency maintain flexibility reallocate manufacturing capacity pharmaceutical production process complex highly regulate vary widely product product give shift add manufacturing capacity lengthy process require significant capital expenditure regulatory approval maintain operate flexible manufacturing network consist internal external resource minimize unnecessary product transfer inefficient use manufacturing capacity discussion regulatory impact manufacturing refer government regulation price constraint significant pharmaceutical manufacturing facility locate puerto rico france italy require significant ongoing capital investment maintenance compliance increase regulatory requirement addition product portfolio change year expect continue modification exist manufacturing network meet complex processing standard require newly introduce product include biologic biologic manufacturing involve complex process traditional pharmaceutical operation fda approve large scale multi product bulk biologic manufacturing facility deven massachusetts continue capital investment facility startup phase new largescale biologic manufacturing facility cruiserath ireland expect operational rely party manufacture supply portion active product ingredient drug substance necessary manufacture product opdivo sprycel yervoy eliquis orencia baraclude reyataz sustiva franchise continue shift party manufacture supply establish brand maintain stable supply product variety action include inventory management maintenance additional quantity material possible design provide reasonable level ingredient hold thirdparty supplier manufacturing operation interrupt certain supply arrangement extend multiple year minimum purchase obligation determine expect near longterm demand requirement additional protection case step maintain approve backup source available example capability manufacture opdivo internally arrangement thirdparty manufacturer meet demand connection divestiture license arrangement distribution agreement certain product certain circumstance enter agreement agree supply product party addition liability arise failure supply product agreement arrangement require invest facility production nonstrategic product result additional regulatory filing obligation cause interruption manufacturing product success depend great measure customer confidence quality product integrity datum support safety effectiveness product quality arise total commitment quality part operation include research development purchasing facility planning manufacturing distribution maintain record demonstrate quality integrity technical information production process control production process involves establish specification standard ingredient equipment facility manufacturing method operation packaging material labeling perform test stage production process final product product sample hold stability ensure product meet regulatory requirement conform standard test involve chemical physical analyse microbiological testing combination analyse quality control testing provide business unitsite thirdparty laboratory quality assurance group routinely monitor manufacturing procedure system subsidiary thirdparty supplier assure quality compliance requirement meet environmental regulation facility operation subject extensive foreign law regulation relate environmental protection human health safety include govern discharge pollutant air water use management disposal hazardous radioactive biological material waste cleanup contamination pollution control permit require operation permit subject modification renewal revocation issue authority environment health safety group monitor operation world provide overview regulatory requirement oversee implementation standard compliance incur operating capital cost matter ongoing basis material addition invest project reduce resource use energy water believe substantial compliance applicable environmental health safety requirement permit require operation incur additional cost include civil criminal fine penalty cleanup cost thirdparty claim property damage personal injury violation liabilitie law current facility operation year time operator facility generate store dispose substance waste consider hazardous federal state andor foreign environmental law include cercla result soil groundwater certain facility contaminate require significant expenditure investigate control remediate contamination case provide compensation andor restoration damage natural resource currently involve investigation remediation current facility identify prp applicable law environmental condition approximately waste disposal reprocess facility operate party investigation andor remediation activity ongoing face liability cercla federal state foreign law entire cost investigation remediation contaminate site natural resource damage regardless fault ownership time disposal release addition certain site bear remediation responsibility pursuant contractual obligation generally thirdparty operator site involve multiple prps liability expect apportion base nature hazardous substance dispose party site number financially viable prps additional information matter refer item financial statementsnote legal proceeding contingency employee approximately employee december foreign operation significant operation outside conduct subsidiary distributor international operation subject certain risk inherent conduct business abroad include limited currency fluctuation possible nationalization expropriation price exchange control counterfeit product limitation foreign participation local enterprise restrictive governmental action international business subject governmentimpose constraint include law price reimbursement use product bristolmyer squibb website internet website address wwwbmscom website available free charge annual quarterly current report include amendment report soon reasonably practicable electronically file material furnish material sec information relate corporate governance bristolmyer squibb include principle integrity code ethic senior financial officer code business conduct ethic director collectively code corporate governance guideline information concern executive committee board director include board committee committee charter transaction bristolmyers squibb security director executive officer available website investorscorporate governance caption print stockholder request waiver code director executive officer material amendment code business conduct ethic director code ethic senior financial officer post promptly website information relate stockholder service include dividend reinvestment plan direct deposit dividend available website investorsstockholder service caption addition information sustainability program available website responsibility caption incorporate reference certain information part proxy statement annual meeting stockholder sec allow disclose important information refer manner refer information proxy statement annual meeting stockholder annual report available website investorssec filing caption march item risk factor factor describe significantly negatively affect business prospect financial condition operating result credit rating cause trading price common stock decline additional risk uncertainty presently know risk currently consider immaterial impair operation financial condition public announcement datum clinical study competitor news development relate competitor product latestage compound cause significant volatility stock price depend datum result adverse impact business financial condition result operation development key compound combination therapy delay discontinued clinical study meet primary endpoint stock price decline significantly adverse impact business financial condition result operation focus effort resource disease area high unmet need focus portfolio investor place heighten scrutiny product latestage compound particular opdivo backbone portfolio announce multiple regulatory milestone opdivo include early stoppage certain clinical study meet endpoint label expansion new indication experience setback continue development clinical study expect receive datum ongoing clinical study include checkmate combination study firstline lung cancer setting decision health authority potential label expansion announcement datum clinical study competitor news development relate competitor product latestage compound opdivo cause significant volatility stock price depend news result adverse impact business financial condition result operation furthermore announcement negative unexpected datum discontinuation development key compound combination therapy delay anticipate timeline file regulatory approval significant advancement competitor cause stock price decline significantly adverse impact business financial condition result operation assurance datum clinical study support filing regulatory approval key compound prove effective effective compete compound approve key compound commercially successful approve indication depend key product revenue cash flow earning derive majority revenue earning key product prioritize brand comprise approximately revenue growth product opdivo eliquis represent expected increasingly represent significant revenue earning cash flow reduction revenue product adversely impact earning cash flow major product subject issue loss patent protection significant change demand formulary access change material product liability unexpected effect regulatory proceeding negative publicity significant advancement compete product incur adverse impact business financial condition result operation trading price stock experience difficulty delay development commercialization new product compound product appear promise development fail reach market expected optimal timeframe addition product extension additional indication approve furthermore product indication approve fda accelerated approval program contingent verification description clinical benefit confirmatory study study successful example announce pursue accelerate regulatory pathway combination opdivoyervoy lung cancer report negative result checkmate experience negative impact stock price develop commercialize new compound product include inherent risk uncertainty include efficacy safety concern delay deny regulatory approval delay challenge produce product commercial scale excessive cost manufacture failure enter implement optimal alliance development andor commercialization new product iii failure maintain consistent scope variety promise latestage product failure product achieve maintain commercial viability change regulatory approval process cause delay denial new product approval regulatory approval delay especially common product expect risk evaluation mitigation strategy require fda address significant riskbenefit issue inability bring product market significant delay expect approval relate launch date new product negatively impact revenue earning addition certain acquire pipeline program cancel believe commercial prospect reduce recognize material noncash impairment charge program finally lose key molecule intermediary compound library natural manmade disaster act sabotage negatively impact product development cycle face intense competition manufacturer include innovative medicine lowerprice generic product bms dependent market access uptake expansion market brand new product introduction new indication product extension promotional activity alliance partner deliver future growth competition keen include lowerprice generic increasingly aggressive generic commercialization tactic new competitive product enter market particularly iii low price company product real perceive superior efficacy benefit safety risk profile differentiate factor technological advance patent attain competitor clinical study result product competitor product affect value proposition product business combination competitor major thirdparty payer vii compete interest external partnership develop bring new product market unable compete successfully competitor product marketplace material negative impact revenue earning litigation claim infringement intellectual property adversely affect future revenue operate earning party claim infringe intellectual property resolve intellectual property infringement claim costly time consuming require enter license agreement available commercially reasonable term successful claim patent intellectual property infringement subject significant damage injunction prevent manufacture sale use affect product product event material adverse effect profitability financial condition adverse outcome legal matter negatively affect business current future lawsuit claim proceeding government investigation preclude delay commercialization product adversely affect operation profitability liquidity financial condition possible insurance recovery available legal matter include intellectual property dispute adverse decision litigation include product liability commercial case iii antibribery regulation foreign corrupt practice act bribery act include compliance ongoe reporting obligation government result settlement recall withdrawal pharmaceutical product force closing manufacture plant failure fulfill obligation supply contract government customer product pricing promotional matter vii lawsuit claim assert investigation violation security antitrust federal state pricing consumer protection datum privacy law viii environmental health safety sustainability matter tax liability result assessment tax authority lose market exclusivity product early expect pharmaceutical biotechnology industry majority innovative product commercial value realize market exclusivity period country market exclusivity expire generic version approve market biosimilar introduce compete product usually substantial rapid decline product revenue market exclusivity product base patent right certain regulatory form exclusivity scope patent right vary country country dependent availability meaningful legal remedy country failure obtain patent intellectual property right limitation use loss right material country include certain member state basic patent protection product exist certain country historically offer right obtain specific type patent andor licensor file country addition patent environment unpredictable validity enforceability patent predict certainty absent relevant patent protection product datum exclusivity period expire generic version approve market generic biosimilar product manufacturer group seek financial gain increasingly seek challenge patent expire face earlierthanexpecte competition product time patent cover key product likely continue subject patent litigation example february patent sprycel revoke opposition division epo experience decline european revenue entry generic market refer item financial statementsnote legal proceeding contingency information case manufacturer seek regulatory approval submit clinical study datum obtain marketing approval choose launch generic product risk expiration applicable patent andor final resolution relate patent litigation assurance particular product enjoy market exclusivity time period appear estimate disclose assume provide financial guidance addition country india allow competitor manufacture sell compete generic product negatively impact protection afford company lowerprice biosimilar bms biologic product compete biologic negatively impact volume price increase pricing pressure restriction abroad mcos institutional purchaser government agency program negatively affect revenue profit margin product continue subject increase pressure portfolio market access pricing discount restriction region world include rule practice mcos institutional governmental purchasers judicial decision change law regulation federal healthcare program medicare medicaid government action inquirie federal state level law recently enact california vermont nevada new york focus drug pricing transparency andor limit state spend drug iii potential impact change pharmaceutical reimbursement increase pricing pressure medicare formulary medicare reimbursement rate physician commercial formulary general reimbursement delay government price erosion mechanism europe country result deflation pharmaceutical product pricing collection delay failure pay governmentfunde public hospital outside vii impact pricing parallel trade border viii development technology andor industry practice impact reimbursement policy practice thirdparty payer inhibited market access real perceive difference value proposition product compare compete product subject variety international law regulation currently subject number government law regulation future subject new government law regulation cost compliance law regulation negative result noncompliance adversely affect business operating result financial condition company include additional healthcare reform initiative country include additional mandatory discount fee new law regulation judicial governmental decision affect pricing drug reimbursement receivable payment access marketing jurisdiction iii change intellectual property law change accounting standard new increase datum privacy regulation enforcement particularly european union emerge new global regulatory requirement report payment value transfer healthcare professional vii potential impact importation restriction legislative andor regulatory change change tax regulation negatively impact earning subject income taxis country globally particular passage tax cut job act reduce tax rate future earning negatively impact change tax legislation include change tax rate tax base limit phasingout eliminate deduction tax credit tax certain excess income intellectual property change rule earning repatriation change tax law country addition onetime deem repatriation tax approximately billion payable year thirdparty royalty represent significant percentage pretax income operate cash flow enter arrangement entitle potential royalty party outlicense intellectual property commercialization right salesbase contingent proceed relate divestiture business arrangement minimal continue involvement contribute financial success activity royalty continue represent significant percentage pretax income include royalty relate divestiture erbitux diabetes business include transfer certain future royalty right pertain amylin onglyza farxiga product sale sanofi alliance outlicense intellectual property merck patent infringement settlement pretax income generate royalty approximately billion expect increase pretax income adversely affect royalty stream decline future period failure party meet contractual regulatory obligation adversely affect business rely supplier vendor outsource partner alliance partner party research develop manufacture commercialize copromote sell product manage certain marketing sell human resource finance business unit functional service meet contractual regulatory obligation party pose number risk perform standard legal requirement example relation outsource significant clinical development activity innovative medicine contract research organization produce reliable result iii perform timely manner maintain confidentiality proprietary information incur significant cyberattack business disruption dispute arise respect ownership right technology develop partner vii disagreement cause delay termination research development commercialization product result litigation arbitration party locate market subject political social risk corruption infrastructure problem natural disaster addition country specific privacy datum security risk give current legal regulatory environment failure critical party meet obligation include future royalty milestone payment adequately deploy business continuity plan event crisis andor satisfactorily resolve significant disagreement address factor material adverse impact operation result addition party violate allege violate law regulation include local pharmaceutical code foreign corrupt practice act bribery act similar law regulation performance obligation possible suffer financial reputational harm negative outcome include possible legal consequence failure execute business strategy adversely impact growth profitability strategy focus deliver innovative transformational medicine patient unable successfully execute strategy negatively impact future result operation market capitalization connection strategy process evolve operating model focus investment commercial opportunity key brand market accelerate pipeline streamline operation realign manufacturing capability broaden biologic capability thing ability successfully execute operating model evolution impact result able achieve cost saving expect negatively impact operate margin earning result addition unable consistently maintain adequate pipeline internal program transaction party support future revenue growth competition pharmaceutical company acquisition product licensing opportunity intense able locate suitable acquisition target license partner reasonable price successfully execute transaction unable support grow market product successfully execute launch newly approve product advance latestage pipeline manage change operating model evolution manage cost effectively operate result financial condition negatively impact failure attract retain highly qualified personnel affect ability successfully develop commercialize product success largely dependent continue ability attract retain highly qualified scientific technical management personnel personnel expertise clinical governmental regulation commercialization competition qualified personnel biopharmaceutical field intense sure able attract retain quality personnel cost materially increase business asset acquire future underperform able successfully integrate exist business essential component strategy business development activity seek source innovation externally supplement discovery development effort acquire inlicense number asset expect continue support pipeline compound product obtain licensing acquisition future revenue profit cash flow acquire company product technology pipeline candidate materialize low product uptake delay miss pipeline opportunity inability capture expect synergy increase competition safety concern regulatory issue supply chain problem factor control example discontinue development phase development treatment breast gastric cancer consequently exercise option purchase fstar alpha result record iprd charge million substantial difficulty cost delay result integrate acquisition include manufacturing distribution sale marketing promotion information technology activity policy procedure process control compliance iii tax consideration experience difficulty delay manufacture distribution sale product product supply relate patient access negatively impact thing product seizure recall force closing manufacture plant failure failure supplier comply cgmp applicable regulation quality assurance guideline lead manufacturing shutdown product shortage delay product manufacture iii manufacturing quality assurancequality control supply problem governmental approval delay failure sole source single source supplier provide necessary raw material supply finish good reasonable timeframe require quality failure thirdparty manufacturer supply bulk active finished product time construction regulatory approval delay new facility expansion exist facility include intended support future demand biologic product opdivo vii failure meet new emerge regulation require product track distribution channel unique identifier verify authenticity supply chain viii manufacturing distribution issue include limit manufacturing capacity change type product produce biologic physical limitation business interruption disruption supply chain continuity include natural disaster act war terrorism external factor control impact facility critical supplier example new biologic manufacturing facility cruiserath ireland expect operational delay plan opening site impact supply product require obtain product supply party significant cost manufacturing commercial operation puerto rico impact recent hurricane manufacturing site sustain damage currently operate reduce capacity continue work restore normal operation disruption ability operate puerto rico manufacturing facility problem facility infrastructure service available island unavailability raw material supply vendor unavailability key staff materially adversely affect ability supply product affect product sale product label change market product result negative impact revenue profit margin regulatory authority need change label pharmaceutical product include product market year change result additional datum postmarkete study headtohead study adverse event report study identify biomarker objective characteristic indicate particular response product therapy study postmarkete experience produce important additional information product new information add product label affect riskbenefit profile lead potential recall withdrawal decline revenue product liability claim additional information study identify portion patient population nonresponsive medicine high risk adverse reaction label change base study limit patient population study provide additional information sponsor sponsor competitor insurance company government institution manage care organization scientist investigator interested party additional safety efficacy information study assist healthcare provider identify good patient population product negatively impact revenue inventory return limit patient population go forward additionally certain study result especially headtohead study affect product formulary listing adversely affect revenue illegal distribution sale party counterfeit unregistered version product steal product negative impact revenue earning reputation business party illegally distribute sell counterfeit version product meet rigorous manufacturing testing standard patient receive counterfeit drug risk number dangerous health consequence reputation business suffer harm result counterfeit drug sell brand theft inventory warehouse plant intransit properly store later sell unauthorized channel adversely impact patient safety reputation business addition diversion product authorize market channel result reduced revenue negatively affect profitability dependent information technology system infrastructure face certain risk include cybersecurity breach datum leakage rely extensively system network service include internet site data host processing facility tool physical security system hardware software technical application platform manage host provide andor thirdpartie vendor assist conduct business significant breakdown invasion corruption destruction interruption critical information technology system infrastructure workforce authorize access system unauthorized person negatively impact operation everincrease use evolution technology include cloudbase computing create opportunity unintentional dissemination intentional destruction confidential information store thirdparty provider system portable medium storage device experience business interruption theft confidential information reputational damage industrial espionage attack malware cyberattack compromise system infrastructure lead datum leakage internally thirdparty provider aggregate impact operation financial condition material date target event nature expect continue cybersecurity threat rapidly evolve sophistication prevalent industry invest industry appropriate protection monitor practice datum reduce risk continue monitor system ongoing basis current potential threat maintain cyber insurance insurance sufficient cover financial legal business reputational loss result interruption breach system assurance continue effort prevent breakdown breach thirdparty provider database system adversely affect business adverse change global regional local economic political condition adversely affect profitability global economic political risk pose significant challenge company growth profitability difficult mitigate generate approximately revenue outside revenue earning cash flow expose risk strengthen dollar exposure customer credit risk europe south america market include governmentguaranteed hospital receivables market payment receive time significant operation europe include manufacture distribution result operation negatively impact member country exit eurozone monetary union include planned exit note exit impact research commercial general business operation addition future pension plan funding requirement continue sensitive global economic condition relate impact equity market additionally disruption credit market downgrade current credit rating increase future borrowing cost impair ability access capital credit market term commercially acceptable adversely affect liquidity capital resource significantly increase cost capital finally business operation adversely affect political volatility conflict crise individual country region include terrorist activity war guarantee pay dividend repurchase stock declaration time dividend fall discretion board director board decision depend factor include financial condition earning capital requirement debt service obligation industry practice legal requirement regulatory constraint factor board director deem relevant reduction elimination dividend payment dividend program adversely affect stock price addition time decide buy share market adversely affect stock price increase use social medium platform present risk challenge increase use social medium communicate company news event inappropriate andor unauthorized use certain medium vehicle cause brand damage information leakage lead legal implication include improper collection andor dissemination personally identifiable information employee patient healthcare professional stakeholder addition negative inaccurate post comment social network website damage reputation brand image goodwill disclosure nonpublic companysensitive information workforce external medium channel lead information loss identify new point entry social medium continue expand present new challenge item unresolved staff comment item property principal executive office locate park avenue new york lease manufacturing administration storage distribution facility approximately site worldwide believe manufacturing property combination thirdparty manufacturer provide adequate production capacity current operation information manufacturing property refer item businessmanufacture quality assurance significant manufacturing location geographic area follow december manufacturing united states europe total item legal proceeding information pertain legal proceeding find item financial statementsnote legal proceeding contingency incorporate reference item safety disclosure applicable executive officer registrant list information executive officer february executive officer elect board director initial term continue board meeting follow annual meeting stockholder elect oneyear term successor elect executive officer serve discretion board director current position age employment history past year giovanni caforio president pharmaceuticals chairman board chief executive officer executive vice president chief commercial officer member leadership team chief operating officer director company chief executive officer director company present chairman board chief executive officer charle bancroft chief financial officer executive vice president global services chief financial officer executive vice president present chief financial officer executive vice president global business global business operation operation member leadership team joseph caldarella present senior vice president corporate controller senior vice president corporate controller john elicker senior vice president public affairs investor relation senior vice president corporate affair investor present senior vice president corporate affair investor relation relation member leadership team murdo gordon senior vice president oncology immunology executive vice president chief commercial officer president pharmaceuticals member leadership team senior vice president head worldwide market present executive vice president chief commercial officer ann powell judge chief human resource officer shire pharmaceutical senior vice president chief human resource senior vice president global human resource officer present senior vice president chief human resource officer member leadership team sandra leung general counsel corporate secretary executive vice president general counsel executive vice president general counsel corporate secretary member leadership team present executive vice president general counsel thomas lynch present executive vice president chief scientific officer executive vice president chief scientific officer member leadership team louis schmukler president global product development supply senior vice president president global product present senior vice president president global product development supply development supply member leadership team paul von autenrie senior vice president enterprise service chief information officer senior vice president chief information officer present senior vice president chief information officer member leadership team item market registrant common stock stockholder matter market price bristolmyer squibb common stock trade new york stock exchange symbol bmy quarterly summary high low closing market price present high low high low common quarter second quarter quarter fourth quarter holder common stock number record holder common stock december number record holder base actual number holder register book date include holder share street name person partnership association corporation entity identify security position listing maintain depository trust company dividend board director declare follow quarterly dividend share pay period indicate common prefer quarter second quarter quarter fourth quarter december board director declare quarterly dividend share common stock pay february shareholders record january board director declare quarterly dividend share prefer stock payable march shareholders record february unregistere sale equity security use proceed follow table summarize surrender equity security month end december total number share approximate dollar value average price purchase share total number pay publicly announce purchase period share purchaseda sharea programsb programsb dollar million share datum october november december month end december include share repurchase publicly announce program share common stock surrender company satisfy tax withholding obligation connection vest award longterm incentive program board director authorize repurchase billion common stock june increase authorization repurchase common stock additional billion october board director approve new share repurchase program authorize repurchase additional billion common stock stock repurchase program expiration date item select financial datum year financial summary amount million share datum income statement dataa total revenue net earning net earningsloss attributable noncontrolle interest bms net earning common share attributable bms basic diluted average common share outstanding basic diluted cash dividend pay bms common prefer stock cash dividend declare common share financial position datum december cash cash equivalent marketable securitiesb total asset longterm debtb equity discussion item affect comparability result year refer item management discussion analysis financial condition result operationsnongaap financial measure include current noncurrent portion item management discussion analysis financial condition result operation executive summary bristolmyers squibb company global specialty biopharmaceutical company mission discover develop deliver innovative medicine help patient prevail disease refer summary abbreviate term end term document receive approval new medicine additional indication formulation currently market medicine major market japan china include multiple regulatory milestone achievement opdivo commit investigate opdivo combination yervoy anticancer agent wide array tumor type include broad program lung head neck liver kidney bladder gastric continue believe breadth depth portfolio position future new compound clinical development study different tumor type addition advance certain nonio programs pipeline include fgf treatment nash tyk inhibitor treatment immune disease psoriasis continue progress company transformation initiative enable invest high priority portfolio opportunity revenue increase result high demand prioritize brand include opdivo eliquis partially offset increase competition establish brand primarily daklinza decrease gaap ep tax charge attribute tax reform share less extent high license asset acquisition restructuring relate charge low divestiture relate income item partially offset high revenue royalty licensing income patentinfringement settlement adjust impact tax reform specify item nongaap eps increase primarily result high revenue partially offset product mix high expense support opdivo programs revenues increase result high demand prioritize brand include opdivo eliquis partially offset expiration commercialization right abilify transfer erbitux right north america increase competition reyataz sustiva baraclude certain market increase gaap eps high revenue divestiturerelate income low license asset acquisition charge partially offset high opdivo relate expense adjust impact divestiture gain license asset acquisition charge specify item nongaap eps increase primarily result high revenue partially offset product mix highlight follow table summarize financial information year end december dollar million share datum total revenue dilute earning share gaap nongaap nongaap financial measure include nongaap earning relate eps information adjust exclude specify item represent certain cost expense gain loss item impact comparability financial result detail list specify item information reconciliation nongaap financial measure refer nongaap financial measure significant product pipeline approval follow summary significant approval receive product date approval fda approval injection intravenous use adjuvant treatment patient melanoma december involvement lymph nodes metastatic disease undergo complete resection fda approval treatment patient hcc type liver cancer previously treat sorafenib september approval japan treatment unresectable advanced recurrent gastric cancer progress chemotherapy receive alliance partner ono fda approval treatment adult pediatric patient msih dmmr mcrc opdivo august progress follow treatment fluoropyrimidine oxaliplatin irinotecan approval treatment patient previously treat locally advanced unresectable metastatic june urothelial carcinoma type bladder cancer adult failure platinumcontaine therapy april approval treatment scchn adult progress platinumbase therapy march approval japan treatment recurrent metastatic hnc receive alliance partner ono fda approval treatment patient previously treat locally advanced metastatic urothelial february carcinoma approval treatment active psa adult response previous diseasemodifying antirheumatic drug therapy include methotrexate inadequate additional systemic therapy july psoriatic skin lesion require orencia fda approval treatment active psa adult fda approval new subcutaneous administration option use patient year age old march moderately severely active polyarticular jia fda expand indication sprycel tablet include treatment child philadelphia sprycel november chromosomepositive cml chronic phase fda approval expand indication treatment unresectable metastatic melanoma pediatric yervoy july patients china fda approval daklinza sunvepra regiman treatmentnaive experienced patient hepatitis franchise april infected genotype chronic hcv addition daklinza approve china combination use agent include sofosbuvir adult patient hcv genotype infection refer product pipeline development development market product latestage pipeline early strategy focus specialty biopharmaceutical company discover develop deliver transformational medicine address unmet medical need strategy combine resource scale capability pharmaceutical company speed focus innovation biotech industry strategic priority drive business performance continue build lead franchise maintain diversified portfolio outside continue discipline approach capital allocation include establish partnership collaboration inlicense acquire investigational compound essential component successfully deliver transformational medicine patient develop new medicine follow core therapeutic area oncology priority immunoscience priority lupus rheumatoid arthritis inflammatory bowel disease cardiovascular priority heart disease fibrotic disease priority lung liver continue advance wave innovative medicine invest significantly pipeline internally business development activity continue invest monotherapy study combination approach wave early asset enter collaboration agreement expand research develop opdivo approve investigational oncology agent combination regimen remain focused resource cancer development program seek broaden use opdivo early line therapy expand new tumor accelerate wave mechanism develop treatment option refractory patient cancer continue advance early stage portfolio immunoscience cardiovascular fibrotic disease strengthen partnership diverse group company academic institution new expand research activity believe differentiate internal external focus contribute advance pipeline potentially transformational medicine commercial model evolve revenue market product portfolio continue grow demonstrate strong execution strategy continue drive growth opdivo expand additional indication tumor type monotherapy combination yervoy anticancer agent eliquis continue grow leverage good class clinical profile extensive real world datum number novel oral anticoagulant total prescription build continue success prioritize brand remain strongly commit orencia sprycel operating model transformation commercial infrastructure uniquely leverage potential growth operating model continue evolve successful focus commercial resource prioritize brand market strengthen capability tumor biology patient selection new biomarker deliver lean administrative function streamline manufacture network reflect importance biologic current future portfolio evolution operating model enable deliver necessary strategic financial operational flexibility invest high priority opportunity portfolio look ahead continue implement biopharma strategy drive growth key brand execute product launch invest diverse innovative pipeline aid strategic business development focus prioritize market increase investment biologic manufacturing capability maintain culture continuous improvement acquisition licensing arrangement acquisition licensing arrangement allow focus resource growth opportunity drive great longterm value focus follow core therapeutic area oncology include immunoscience cardiovascular fibrosis significant arrangement past year summarize refer item financial statementsnote acquisition divestiture license arrangement information arrangement ono bms acquire exclusive license develop commercialize ono onos prostaglandin receptor antagonist treatment cancer bm acquire worldwide right japan south korea taiwan add exist collaboration china asean country ono retain exclusive right halozyme bms halozyme enter global collaboration license agreement develop subcutaneously administer bms medicine halozyme enhanze drugdelivery technology allow rapid delivery large volume injectable medication ifm bms acquire outstanding share ifm provide bms right ifm preclinical sting nlrp agonist program focus enhance innate immune response treat cancer biogen bms outlicense biogen exclusive right develop commercialize bms antietau compound development progressive supranuclear palsy roche bms outlicense roche exclusive right develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy cytomx bms cytomx expand initial strategic collaboration discover novel cancer treatment therapy include additional target cytomxs proprietary probody platform treatment cancer arrangement psioxus bms acquire exclusive worldwide right psioxus preclinical stage armed oncolytic virus goal address solid tumor padlock bms acquire outstanding share padlock provide bms right padlock pad inhibitor discovery program focus development treatment approach patient rheumatoid arthritis cormorant bms acquire outstanding share cormorant provide bms right cormorant lead candidate humaxil monoclonal antibody represent potentially complementary mechanism action tcell direct antibodie costimulatory molecules nitto denko bms acquire exclusive worldwide license develop commercialize nitto denko investigational sirna molecule target heat shock protein hsp vitamin contain formulation include nitto denko lead asset ndls currently development treatment advance liver fibrosis option receive exclusive license hsp sirnas vitamin contain formulation treatment lung organ fibrosis arrangement flexus bms acquire outstanding share flexus provide bms right preclinical small molecule idoinhibitor target immunotherapy potential combination bms immunooncology portfolio addition transaction include flexus idotdo discovery program include idoselective idotdo dual tdoselective compound cardioxyl bms acquire outstanding share cardioxyl provide bms right cxl nitroxyl prodrug development acute decompensate heart failure prime bms prime enter exclusive worldwide licensing collaboration agreement develop commercialize prime csfr antibody program include cabiralizumab currently development indication pvn bms responsible development manufacturing commercialization cabiralizumab subject prime option conduct certain study cost develop cabiralizumab pvns combination internal oncology pipeline asset promedior bms acquire warrant provide bms exclusive right acquire promedior lead asset prm develop treatment ipf warrant exercisable provide datum follow completion ipf phase clinical study direct promedior bavarian nordic bms acquire exclusive option globally license commercialize prostvac bavarian nordics investigational phase iii prostatespecific antigentargete cancer immunotherapy development treatment asymptomatic minimally symptomatic metastatic castrationresistant prostate cancer independent datum monitor committee determine continuation phase iii prospect study prostvac patient metastatic castrationresistant prostate cancer futile uniqure bms enter collaboration license agreement uniqure grant bms exclusive license uniqure gene therapy technology platform specific collaboration target collaboration include uniqure proprietary gene therapy program congestive heart failure intend restore heart ability synthesize calcium sensor master regulator heart function improve clinical outcome patient reduce ejection fraction result operation regional revenue composition change revenue follow year end december total revenue analysis change analysis change total foreign total foreign dollar million change exchangeb change exchangeb united states europe rest world othera total revenue include royalty alliancerelate revenue product sell regional commercial organization foreign exchange impact derive apply prior period average currency rate current period sale revenue increase high demand eliquis opdivo partially offset low demand establish brand increase competition primarily daklinza hiv brand low growth rate additional competition opdivo daklinza average net selling price approximately high chargeback rebate discount refer product revenue commentary additional information revenue increase high demand opdivo eliquis daklinza partially offset year impact expirationtransfer commercialization right abilify erbitux average net selling price approximately high chargeback rebate discount europe revenue increase high demand opdivo eliquis partially offset low demand daklinza increase competition europe revenue increase high demand opdivo eliquis partially offset low demand yervoy rest world revenue decrease low demand establish brand include daklinza increase competition outlicense mature brand product partially offset high demand opdivo eliquis rest world revenue decrease increase competition hepatitis franchise japan unfavorable foreign exchange primarily latin america partially offset high demand opdivo eliquis revenue decrease result expiration certain supply arrangement refer item financial statementsnote alliance discussion alliance single country outside contribute total revenue japan contribute total revenue gtn adjustment recognize revenue net gtn adjustment describe critical accounting policy share certain abilify atripla revenue reflect net gtn adjustment alliance revenue activity end reserve balance significant category gtn adjustment follow rebate chargeback medicaid medicare return discount dollar million cash discount rebate adjustment total balance january provision relate sale current period prior period payment return foreign currency translation balance december provision relate sale current period prior period payment return foreign currency translation balance december reconciliation gross product sale net product sale significant category gtn adjustment follow exclude alliance revenues abilify atripla year end december change dollar million gross product sale gtn adjustment chargeback cash discount medicaid medicare rebate rebate return discount adjustment total gtn adjustment net product sale gtn adjustment percentage nonus gtn adjustment primarily function product sale volume regional payer channel mix contractual legislative discount rebate gtn adjustment increase high rate gross product sale high eliquis gross product sale relatively high gtn adjustment percentage result competitive pressure maintain position healthcare payer formulary allow patient continue access medical plan product revenue year end december change dollar million prioritize brand opdivo nonus eliquis nonus orencia nonus sprycel nonus yervoy nonus empliciti nonu establish brand baraclude nonus sustiva franchise nonus reyataz franchise nonus hepatitis franchise nonus brand nonus total revenue nonus change excess opdivo nivolumab fully human monoclonal antibody bind nkt cell approve anticancer indication include bladder blood colon head neck kidney liver lung melanoma stomach continues investigate tumor type disease area revenue increase period high demand expect increase competition opdivo continue future new product entrant expand indication international revenue increase period high demand result launch additional indication approval new country eliquis apixaban oral factor inhibitor target stroke prevention adult patient nonvalvular atrial fibrillation prevention treatment vte disorder international revenue increase period high demand result increase commercial acceptance novel oral anticoagulant market share gain orencia abatacept fusion protein indicate adult patient moderate severe active psa indicate reduce sign symptom certain pediatric patient moderately severely active polyarticular juvenile idiopathic arthritis revenue increase period high average net selling price demand international revenue increase period high demand sprycel dasatinib oral inhibitor multiple tyrosine kinase indicate firstline treatment adult philadelphia chromosomepositive chronic myeloid leukemia chronic phase treatment adult chronic accelerate myeloid lymphoid blast phase cml resistance intolerance prior therapy include gleevec imatinib meslylate revenue increase period high demand average net selling price international revenue increase period high demand experience decline european revenue event generic datasinib product enter market yervoy ipilimumab monoclonal antibody treatment patient unresectable metastatic melanoma revenue increase period primarily high demand international revenue increase high demand europe follow approval opdivoyervoy combination therapy melanoma international revenue decrease low demand result introduction product treat patient melanoma include opdivo empliciti elotuzumab humanized monoclonal antibody treatment multiple myeloma empliciti launch december japan september baraclude entecavir oral antiviral agent treatment chronic hepatitis international revenue continue decrease period low demand result increase competition sustiva efavirenz franchise nonnucleoside reverse transcriptase inhibitor treatment hiv include sustiva antiretroviral drug bulk efavirenz include combination therapy atripla revenue continue decrease period low demand result increase competition new product entrant decrease partially offset high average net selling price loe occur december gilead terminate bms participation canada joint venture follow launch generic version sustiva result bms share atripla revenue decline year refer item financial statementsnote alliance discussion reyataz atazanavir sulfate franchise include reyataz protease inhibitor treatment hiv evotaz atazanavir cobicistat combination therapy contain reyataz tybost cobicistat revenue continue decrease low demand result new product entrant decrease partially offset high average net selling price loe occur december result high decline revenue future period generic competition international revenue continue decrease period low demand result increase competition decrease impact unfavorable foreign exchange hepatitis franchise daklinza daclatasvir nsa replication complex inhibitor sunvepra asunaprevir protease inhibitor beclabuvir nsb inhibitor revenue decrease low demand result new product entrant revenue increase launch daklinza july international revenues decrease period low demand result increase competition new product entrant brand include brand include lose exclusivity major market otc brand royalty revenue revenue decrease expiration bms commercialization right abilify april transfer bms north american erbitux rights lilly october refer item financial statementsnote alliance discussion international revenue decrease outlicense divestiture certain brand continue generic erosion international revenue decrease expiration certain supply arrangement divestiture certain brand increase competition otc brand unfavorable foreign exchange estimate endus demand pursuant sec consent order describe sec consent order monitor level inventory hand wholesaler distribution channel outside direct customer distribution channel obligate disclose product level inventory excess month hand expect demand subject minimis exception estimate level inventory distribution channel excess month hand follow product material result operation date indicate december daklinza month inventory hand result minimum require stock level support patient demand expect inventory hand level daklinza exceed month near term international product estimate level inventory distribution channel excess month hand september dafalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily attributable france support product seasonality efferalgan analgesic product sell principally europe month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily attributable france support product seasonality fervex cold flu product month inventory hand direct customer compare month inventory hand june level inventory hand attributable france support product seasonality perfalgan analgesic product month inventory hand internationally direct customer compare month inventory hand june level inventory hand primarily gulf country extend delivery lead time generally determine month hand estimate inventory level product hand outmovement provide large wholesaler account approximately total gross sale product factor influence estimate include generic competition seasonality product wholesaler purchase light increase wholesaler list price new product launch new warehouse opening wholesaler new customer stocking wholesaler addition estimate calculate thirdparty datum impact recordkeeping process nonus business significantly direct customer information available direct customer product level inventory correspond movement information reliability thirdparty demand information vary widely limit direct customer sale channel inventory report influence demand information exist available develop variety methodology estimate datum include historical sale direct customer thirdparty market research datum relate prescription trend endus demand give difficulty inherent estimate thirdparty demand information evaluate methodology estimate direct customer product level inventory calculate month hand ongoing basis change necessary factor affect estimate include generic competition seasonality product price increase new product launch new warehouse opening direct customer new customer stocking direct customer expect direct customer purchase governmental bidding situation information require estimate month hand direct customer distribution channel nonus business year end december available prior file annual report disclose product level inventory excess month hand expect demand subject minimis exception quarterly report form expense change dollar million cost product sell marketing sell administrative research development income net total expense change excess cost product sell cost product sell include material internal labor overhead cost own manufacturing site thirdparty product supply cost supply chain cost manage global manufacturing supply organization cost product sell include royalty profit share certain excise taxis foreign currency hedge settlement gain loss amortization acquire develop technology cost cost product sell typically vary period result product mix volume particularly royaltie profit share less extent change foreign currency price inflation cost attribute manufacturing site exit cost product sell increase high eliquis profit share million million impairment charge reduce carry value small molecule active pharmaceutical ingredient manufacturing operation sword ireland remain increase primarily high sale volume inventory charge manufacture startup cost foreign currency refer item financial statementsnote acquisition divestiture license arrangement information cost product sell increase high eliquis profit share million low foreign currency hedge settlement gain high puerto rico excise tax marketing sell administrative marketing sell administrative expense primarily include salary benefit cost thirdparty professional marketing fee outsource fee shipping handling cost advertising product promotion expense manage regional commercialization organization global enable function finance legal information technology human resource certain expense share alliance partner base contractual agreement expense typically vary period new product launch promotional activity marketing sell administrative expense decrease low advertising promotion salesforce expense support daklinza establish brand low bms foundation grant marketing sell administrative expense increase high advertising promotion salesforce expense support opdivo partially offset low spend establish brand favorable foreign exchange research development research development activity include discovery research preclinical clinical development drug formulation medical support market product expense include salary benefit cost thirdparty grant fee pay clinical research organization supply upfront contingent milestone payment license asset acquisition investigational compound iprd impairment charge proportionate allocation enterprisewide cost allocation include facility information technology employee stock compensation cost appropriate cost certain expense share alliance partner base contractual agreement expense typically vary period number reason include time license asset acquisition charge iprd impairment charge research development expense increase high license asset acquisition charge site exit charge iprd impairment charge expansion opdivo development program research development expense decrease low license asset acquisition iprd impairment charge partially offset acceleration expansion opdivo development program significant charge include expense follow year end december dollar millions ifm cytomx halozyme flexus cardioxyl psioxus ono padlock cormorant nitto denko prime promedior bavarian nordic uniqure license asset acquisition charge fstar alpha lpa antagonist iprd impairment site exit cost site exit cost research development significant charge upfront payment milestone payment option fee license asset acquisition charge result strategic transaction acquire license certain investigational oncology cardiovascular immunoscience fibrotic disease compound option acquire license disclose acquisition licensing arrangement iprd impairment charge relate discontinue development investigational compound alliance fstar alpha lpa antagonist phase study site exit cost result expect exit site primarily reduction estimate useful life relate asset impairment charge reduce carry value facility wallingford connecticut income net income net increase primarily patent infringement settlement outlicense income partially offset low divestiture gain relate service fee high restructure debt redemption charge income net increase primarily divestiture gain relate service fee royaltie low debt redemption litigation charge component income net follow year end december dollar million interest expense investment income provision restructure litigation settlement equity net income affiliate divestiture gain royalty license income transition service fee pension charge intangible asset impairment equity investment impairment write option adjustment loss debt redemption income net restructuring charge relate change company operating model drive continue success near longterm focus investment commercial opportunity key brand market competitive agile organization accelerate pipeline streamline operation realign manufacturing capability broaden biologic capability reflect current future portfolio streamline simplify smallmolecule supply network new operating model expect enable company deliver strategic financial operational flexibility necessary invest high priority company aggregate restructuring charge million incur action include accelerate depreciation impairment charge result early site exit litigation settlement include bms share patentinfringement settlement relate merck antibody keytruda bms ono sign global patent license agreement merck merck initial payment million bms ono bms receive million merck obligate pay ongoing royalty global sales keytruda january december january december company grant certain right respective patent portfolio pertain payment royalty share bms ono percent allocation respectively adjust party legal fee divestiture gain relate additional contingent consideration diabete business certain otc brand investigational hiv medicine business mount vernon indiana manufacturing facility erbitux ixempra certain otc product business royalty licensing income include upfront licensing fee biogen roche connection outlicense certain investigational genetically define disease compound royalty merck patent infringement settlement contingent consideration erbitux diabetes business divestiture including transfer certain royalty right pertain amylin product sale transition service fee include fee result divestiture diabete investigational hiv medicine business pension charge consist primarily settlement charge magnitude lump sum payment principal pension plan write option adjustment include income million result change fair value write option liability attribute reckitt alliance loss debt redemption result repurchase certain longterm debt obligation early redemption euro note tender offer certain debt security income taxis dollar million earning income taxis provision income taxis effective tax rate new tax reform legislation enact december know tax cut job act act act move worldwide tax system quasiterritorial tax system comprise broad complex change tax code include limited reduce tax rate add deem repatriation transition tax certain foreign earning profit generally eliminate federal income taxis dividend foreign subsidiary include certain income control foreign company taxable income create new minimum tax refer base erosion antiabuse income tax limit certain researchbase credit eliminate domestic manufacturing deduction aspect act effective additional tax expense billion recognize fourth quarter enactment act additional expense increase effective tax rate include billion onetime deem repatriation transition tax previously untaxe post foreign earning profit include related tax reserve earning effectively tax rate extent specify foreign corporation hold cash certain asset rate remain earning profit remain million additional tax expense include adjustment measure net defer tax asset new tax rate accounting reduction defer tax asset tax rate complete tax charge deem repatriation tax incomplete record provisional able reasonable estimate tax provisional amount change complete finalize untaxed post foreign earning profit relate cash certain eligible asset specify foreign corporation provisional amount change additional guidance relevant tax code release exclude transitional impact relate act tax impact attribute nondeductible charge divestiture transaction specify item increase effective tax rate tax benefit attribute charge incur connection acquisition ifm cormorant padlock cardioxyl flexus warrant acquire promedior lower nondeductible goodwill allocate business divestiture high valuation allowance attribute capital loss carryforward release impact effective tax rate addition adoption amend income tax accounting guidance relate sharebased payment early adoption intraentity transfer asset inventory reduce effective tax rate earning mix high low tax jurisdiction domestic manufacturing deduction high foreign tax credit result puerto rico excise tax attribute remain change effective tax rate prior act effective income tax rate typically lower statutory rate primarily earning certain manufacturing operation low tax jurisdiction switzerland ireland puerto rico indefinitely reinveste bms operate favorable tax grant puerto rico schedule expire prior company continue assess broad complex change tax code currently expect significant net impact tax reform effective tax rate refer item financial statementsnote income taxis information nongaap financial measure nongaap financial measure include nongaap earning relate eps information adjust exclude certain cost expense gain loss specify item evaluate individual basis item adjust consider quantitative qualitative aspect typically follow characteristic highly variable difficult project unusual nature significant result particular period indicative future operating result similar charge gain recognize prior period likely reoccur future period include restructuring cost accelerate depreciation impairment property plant equipment intangible asset charge connection acquisition license party intellectual property right divestiture gain loss pension legal contractual settlement charge debt redemption gain loss item defer current income taxis attribute item adjust consider individual impact overall tax expense deductibility jurisdictional tax rate nongaap information intend portray result baseline performance supplement enhance management analyst investor overall understanding underlie financial performance facilitate comparison current past future period example nongaap earning ep information indication baseline performance item consider reflective ongoing result addition information primary indicator use basis evaluate performance allocate resource set incentive compensation target planning forecast future period information intend consider isolation substitute net earning dilute eps prepared accordance gaap specify item follow year end december dollar million impairment charge accelerate depreciation shutdown cost cost product sell marketing sell administrative license asset acquisition charge iprd impairment site exit cost research development provision restructure litigation settlement divestiture gain royalty license income pension charge intangible asset impairment write option adjustment loss debt redemption income net increase pretax income income taxis item income taxis attribute tax reform income taxis increase net earning noncontrolle interest increase net earning diluted nongaap ep calculation reconciliations gaap nongaap follow year end december dollar million share datum net earning attributable bms diluted eps calculation gaap specify item net earning attributable bms diluted eps calculation nongaap average common share outstanding dilute diluted eps attributable bms gaap dilute eps attributable specify item dilute eps attributable bms nongaap financial position liquidity capital resource net cash position follow dollar million cash cash equivalent marketable security current marketable security noncurrent total cash cash equivalent marketable security shortterm debt obligation longterm debt net cash position cash cash equivalent marketable security hold approximately billion december remain billion hold primarily lowtax jurisdiction subject restriction withholding taxis certain jurisdiction subject onetime deem repatriation transition tax billion payable year result tax reform expect flexibility access cash future cash generate foreign subsidiary believe exist cash cash equivalent marketable security cash generate operation issuance commercial paper sufficient satisfy normal cash requirement year include dividend capital expenditure milestone payment working capital deem repatriation transition tax maturity longterm debt management continuously evaluate company capital structure ensure company finance efficiently result repurchase common stock debt security termination interest rate swap contract prior maturity issuance debt security company repurchase billion common stock accelerate share repurchase agreement rule plan open market purchase stock repurchase fund billion new longterm debt cash company repay million longterm debt maturity repurchase million longterm debt refer item financial statementsnote financial instrument fair value measurement note equity information issue commercial paper fund nearterm domestic liquidity requirement average commercial paper outstanding million weightedaverage rate maximum commercial paper outstanding billion million outstanding december dividend payment billion billion dividend decision quarterly basis board director annual capital expenditure approximately billion billion million expect approximately billion million continue expand biologic manufacturing capability facilityrelate activity example construct new largescale biologic manufacturing facility ireland produce multiple therapy grow biologic portfolio complete investment portfolio include noncurrent marketable security subject change fair value result interest rate fluctuation market factor investment policy establishe limit time maturity investment institution policy require investment enter corporate financial institution meet high credit quality standard refer item financial statementsnote financial instrument fair value measurement information currently separate revolve credit facility total billion syndicate lender facility provide customary term condition financial covenant day billion facility expire march billion facility extend october july billion fiveyear facility extendable annually year anniversary date consent lender borrowing outstanding revolve credit facility december additional regulation pass future include additional healthcare reform initiative change tax law additional pricing law potential importation restriction reduce result operation operate cash flow liquidity financial flexibility continue monitor potential impact economic condition certain european country relate impact prescription trend pricing discount creditworthiness customer believe economic condition material impact liquidity cash flow financial flexibility credit rating bms longterm shortterm credit rating assign moody investor service prime respectively stable rating outlook bms longterm shortterm credit rating assign standard poor respectively stable rating outlook bms longterm shortterm credit rating assign fitch respectively stable rating outlook longterm rating reflect agency opinion low default risk somewhat susceptible adverse effect change circumstance economic condition shortterm rating reflect agency opinion good extremely strong capacity timely repayment credit rating downgrade affect interest rate debt incur fair market value exist debt ability access capital market generally cash flow follow discussion cash flow activity dollar million cash flow provide byused operating activity invest activity financing activity operate activity cash flow operating activity represent cash receipt disbursement activity invest financing activity operate cash flow derive adjust net earning noncontrolle interest noncash operating item gain loss attribute invest financing activity change operate asset liability result time difference receipt payment cash transaction recognize result operation result change cash operating activity reflect time cash collection customer alliance partner payment supplier alliance partner employee customer discount rebate tax payment ordinary course business example annual employee bonus typically pay quarter subsequent year addition cash collection impact long payment term certain biologic product primarily certain product include opdivo yervoy empliciti day day long payment term closely align insurance reimbursement time physician cancer center follow administration patient billion change cash flow operating activity compare primarily attributable follow item addition increase sale time cash collection payment ordinary course business low income tax payment approximately billion outlicensing proceed million related biogen roche transaction litigation settlement proceed million relate merck antibody keytruda bms share partially offset high licensing payment approximately million primarily cytomx halozyme nitto denko transaction high contribution pension plan approximately million billion change cash flow operating activity compare primarily attributable follow item addition increase sale time cash collection payment ordinary course business winddown abilify alliance approximately million low licensing payment approximately million primarily fiveprime promedior transaction partially offset high income tax payment approximately billion investing activity cash requirement invest activity include cash acquisition manufacturing facilityrelate capital expenditure purchase marketable security maturity great day reduce proceed business divestiture include royalty sale maturity marketable security billion change cash flow investing activity compare primarily attributable low net sale marketable security maturity great day million essentially offset change cash equivalent low business divestiture proceed approximately million primarily certain otc brand investigational hiv medicine business high asset acquisition payment approximately million primarily acquisition ifm billion change cash flow investing activity compare primarily attributable high net sale marketable security approximately billion reinveste cash cash equivalent low asset acquisition payment approximately million primarily acquisition flexus high business divestiture proceed approximately million include royalty contingent consideration receive subsequent divestiture certain otc brand investigational hiv medicine business mount vernon indiana manufacturing facility ixempra mature otc product business partially offset high capital expenditure approximately million financing activity cash requirement financing activity include cash pay dividend repurchase common stock repay longterm debt borrowing reduce proceed exercise stock option issuance longterm debt borrowing billion change cash flow financing activity compare primarily attributable high repurchase common stock billion primarily accelerated share repurchase agreement partially offset high net borrowing activity million primarily fund repurchase common stock billion change cash flow financing activity compare primarily attributable high net borrowing activity approximately billion primarily debt redemption reduction cash overdraft partially offset repurchase common stock approximately million contractual obligation offbalance sheet arrangement payment period contractual obligation december follow obligation expire period dollar million total later year shortterm borrowing longterm debt interest longterm debta operating lease purchase obligation uncertain tax positionsb deem repatriation transition tax total include estimate future interest payment periodic cash settlement derivative include shortterm uncertain tax benefit uncertainty timing resolution exclude pension liability uncertainty timing resolution addition commit aggregate billion potential future research development milestone payment party license asset acquisition development program include earlystage milestone billion milestone achieve phase iii clinical study latestage milestone billion milestone achieve post phase iii clinical study payment generally payable achievement certain developmental regulatory milestone specific timing predict agreement provide salesbased milestone aggregate billion obligate pay alliance partner achievement certain sale level addition royalty certain manufacturing development commercialization obligation connection alliance arrangement practicable estimate obligation refer item financial statementsnote alliance information alliance offbalance sheet arrangement material reasonably likely material financial condition result operation sec consent order fcpa settlement previously disclose august enter final settlement sec concluding investigation concern certain wholesaler inventory accounting matter settlement reach consent copy attach exhibit quarterly report form period end september term consent agree subject certain define exception limit sale product sell direct customer include wholesaler distributor hospital retail outlet pharmacie government purchaser base expect demand amount exceed approximately month inventory hand make timely public disclosure change practice agree consent certain measure implement include establish formal review certification process annual quarterly report file sec establish business risk disclosure group retain outside consultant comprehensively study help reengineer accounting financial reporting process publicly disclose sale incentive offer direct customer purpose induce purchase product excess expect demand ensure budget process give appropriate weight input come adequately document process establish companywide policy limit sale direct customer purpose comply consent policy include adoption procedure monitor limit sale direct customer accordance term consent procedure include governance process escalate appropriate management level potential question concern compliance policy timely resolution question concern addition compliance policy monitor regular basis maintain dsas pharmaceutical wholesaler account nearly gross revenue current term dsas wholesaler customer provide weekly information respect month hand productlevel inventory outmovement product large wholesaler currently account approximately gross revenue inventory information receive wholesaler internal information estimate month hand product level inventory wholesaler estimate month hand product inventory level businesss wholesaler customer large wholesaler extrapolate month hand calculate large wholesaler contrast nonus business significantly direct customer limit information direct customer product level inventory correspond outmovement information reliability thirdparty demand information available vary widely accordingly rely variety method estimate month hand product level inventory business unit believe abovedescribe procedure provide reasonable basis ensure compliance consent addition previously disclose october company reach civil settlement sec allege fcpa violation company agree pay approximately million disgorgement penalty interest settlement company agree twoyear selfmonitore period report government conclude october recently issue accounting standard recently issue accounting standard refer item financial statementsnote accounting policiesrecently issue accounting standard critical accounting policy preparation financial statement require use estimate assumption affect report amount asset liability report amount revenue expense critical accounting policy significantly impact financial condition result operation require difficult subjective complex judgment result need estimate effect matter inherently uncertain uncertainty actual result vary estimate revenue recognition accounting policy revenue recognition substantial impact report result rely certain estimate revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally shipment certain market occur delivery product customer revenue reduce gtn sale adjustment discuss involve significant estimate judgment consider legal interpretation applicable law regulation historical experience payer channel mix medicare medicaid current contract price applicable program unbilled claim processing time lag inventory level distribution channel estimate assess period adjust require revise information actual experience gtn adjustment follow category gtn adjustment involve significant estimate judgment information obtain external source refer total revenue discussion analysis significant category gtn sale adjustment chargeback cash discount business participate program government entity significant department defense department veteran affair party include cover entity drug pricing program pricing product extend wholesaler list price participate entity entity purchase product wholesaler low program price wholesaler charge difference acquisition cost low program price account receivable reduce estimate unprocessed chargeback claim attributable sale typically week time lag certain country cash discount offer incentive prompt payment generally approximate sale price account receivable reduce estimate unprocessed cash discount typically month time lag medicaid medicare rebate business participate state government medicaid program qualify federal state government program require discount rebate participate state local government entity discount rebate provide program include medicaid rebate accrual medicaid rebate extend drug manage medicaid plan estimate unpaid unbilled rebate present liability rebate discount offer manage healthcare organization manage prescription drug program medicare advantage prescription drug plan cover medicare drug benefit pay point service discount center medicare medicaid services medicare beneficiarie coverage gap donut hole estimate unpaid unbilled rebate discount present liability rebate return discount adjustment gtn sale adjustment include sale return program base applicable law regulation individual nonus country rebate offer manage healthcare organization less extent nonus program include different pricing scheme cost cap volume discount outcomebase pricing scheme pricing clawback base sale individual company aggregation company participate specific market estimate unpaid unbilled rebate discount present liability estimate return establish product determine consider historical experience factor include level inventory distribution channel estimate shelf life product recall product discontinuance price change competitive product introduction generic product introduction competitive new product low demand follow loe estimate product return present liability estimate return new product determine consider historical sale return experience similar product product line similar therapeutic area andor similar distribution model defer recognition revenue right return expire sufficient historical experience estimate sale return develop limited circumstance insufficient historical experience product similar therapeutic area distribution method characteristic available typically occur new product extension exist line product historical experience product similar therapeutic category lack estimate level inventory distribution channel project demand consider estimate sale return new product use information external source information external source estimate gtn adjustment estimate inventory wholesaler base project prescription demand base sale product historical inventory experience analysis thirdparty information include write oral information obtain certain wholesaler respect inventory level sellthrough customer thirdparty market research datum internal information inventory information receive wholesaler product recordkeeping process exclude inventory hold intermediary sell retailer hospital continue practice combine retail mail prescription volume retailequivalent basis use methodology internal demand forecast use information external source identify prescription trend patient demand average selling price estimate subject inherent limitation estimate rely thirdparty information certain thirdparty information form estimate reflect limitation include lags date thirdparty information generate date receive thirdparty information retirement benefit account pension postretirement benefit plan require actuarial valuation base significant assumption discount rate expect longterm rate return plan asset consultation actuary significant assumption salary growth retirement turnover healthcare trend mortality rate evaluate select base expectation actual experience remeasurement date pension expense vary range outcome material effect report earning project benefit obligation future cash fund actual result give year differ estimate economic factor yield high quality corporate bond coincide cash flow plan estimate payout determine discount rate citi pension discount curve plan present value benefit obligation december pension plan determine discount rate assume discount rate determine pension plan project benefit obligation december reduce additional project benefit obligation increase approximately million expect longterm rate return plan asset estimate consider expect return individual asset class input external advisor consider longterm historical return include actual performance compare benchmark similar investment plan pension expense determine expect longterm rate return plan asset expect longterm rate return plan asset determine plan pension expense reduce expense increase million detailed discussion retirement benefit refer item financial statementsnote pension postretirement postemployment liabilitie business combination divestiture goodwill intangible asset acquire business combination licensing transaction billion represent total asset december accounting transaction business combination divestiture significantly different asset acquisition divestiture example acquire iprd capitalize business combination expense asset acquisition fair value contingent consideration goodwill recognize business combination transaction likewise portion report unit constitute business divest goodwill associate business include carry value business determine gain loss derecognition goodwill occur asset disposition result important determine business asset group asset acquire divest business define asc business combination integrate set input process capable generate output ability provide return investor owner typical input include longlive asset include intangible asset right use longlived asset intellectual property ability obtain access require resource typical process include strategic operational resource management process typically document evident organized workforce consider factor determine business acquire divest compound development phase commercial product involve example evaluate acquisition ifm cormorant padlock cardioxyl flexus past year conclude significant process transfer transaction account asset acquisition result amount allocate lead investigational compound expense capitalize addition contingent consideration potential development regulatory approval sale base milestone salesbase royalty include purchase price refer item financial statementsnote acquisition divestiture discussion acquisition similarly evaluate divestiture small molecule manufacturing operation sword ireland investigational hiv medicine business business comprise alliance reckitt medicines company valeant pharmaceuticals international inc erbitux ixempra conclude necessary input process transfer consequently transaction account sale business result allocation goodwill million million million carrying value business determine gain sale contingent proceed related divestiture recognize realize conclude input significant process capable generating output transfer outlicense arrangement biogen roche consequently transaction account sale business longlive asset intangible asset include iprd intangible asset billion december include license million million allocate unapproved product develop technology right million capitalize software million iprd million intangible asset assess impairment current fact circumstance warrant review iprd assess annually intangible asset highly vulnerable impairment charge particularly newly acquire asset recently launch product iprd asset initially measure fair value reduction expectation valuation potentially lead impairment common potential risk leading impairment include competition early expect loe pricing pressure adverse regulatory change clinical study result delay failure obtain regulatory approval additional development cost inability achieve expect synergy high operating cost change tax law macroeconomic change complexity estimate fair value intangible asset connection impairment test similar initial valuation consider high risk nature research development industry success rate bring developmental compound market impairment charge likely occur future period recognize million charge fstar alpha phase development treatment breast gastric cancer million bms phase development treatment ipf discussion iprd impairment refer item financial statementsnote goodwill intangible asset property plant equipment property plant equipment test impairment current fact circumstance require review include likely asset dispose prior estimate remain useful life additionally longlive asset periodically review determine change fact circumstance result change estimate useful life asset possibly result acceleration depreciation circumstance exist estimate undiscounted future cash flow generate asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value expectation future cash flow subject change base near longterm production volume margin generate asset potential alternative future use divestiture small molecule active pharmaceutical ingredient manufacturing operation sword ireland sale facility wallingford connecticut result million million impairment charge respectively reduce carry value asset heldforsale fair value accelerate depreciation impairment relate charge certain manufacturing facility million million million additional charge continue occur result company restructuring action announce fourth quarter asset heldforsale follow criterion consider concluding asset classify heldforsale management commitment plan sell availability immediate sale present condition initiation active program identify buyer probability complete sale year actively market sale reasonable price relation current fair value likelihood significant change plan plan withdraw criterion meet balance sheet date net asset present separately balance sheet heldforsale low carrying fair value cost sell long depreciate amortize classified heldforsale example evaluate divestiture small molecule manufacturing operation sword ireland sale facility wallingford connecticut conclude necessary heldforsale criterion meet quarterly period prior complete sale evaluate divestiture investigational hiv medicine business business comprise alliance reckitt lilly conclude necessary heldforsale criterion meet income taxis valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment defer tax asset billion december net valuation allowance billion billion december net valuation allowance billion federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life discuss fully result operation section mda tax charge attribute onetime deem repatriation tax certain foreign earning billion recognize fourth quarter accounting income tax effect act incomplete issuance date financial statement necessary information available prepare analyze complete accounting able reasonable estimate tax record provisional provisional change complete finalize taxable income untaxe post foreign earning profit relate cash certain eligible asset specify foreign corporation provisional amount change additional interpretation relevant tax code release prior mead johnson splitoff follow transaction occur internal spinoff mead johnson share own conversion mead johnson class share class share iii conversion mead johnson company limited liability company transaction splitoff mead johnson exchange offer qualify taxexempt transaction internal revenue code base private letter ruling receive internal revenue service relate conversion mead johnson class share class share outside legal opinion certain assumption representation covenant mead johnson rely future conduct business matter affect tax treatment exchange example current tax law generally create presumption exchange taxable mead johnson shareholders engage transaction result great change stock ownership year period begin year exchange offer establish exchange offer plan series relate transaction effect change ownership internal spinoff exchange offer determine qualify tax exempt transaction transaction subject tax exchange taxable sale market value addition negative basis excess loss account ela exist investment stock mead johnson prior transaction receive opinion outside legal counsel effect likely eliminate ela transaction taxable income respect ela tax law area complex possible internal spinoff exchange offer tax exempt internal revenue code irs assert additional taxable income period respect ela expose additional taxis occur base understand internal revenue code opinion outside legal counsel tax reserve million establish reduce gain disposal mead johnson include discontinued operation agree certain tax relate indemnity mead johnson set forth tax sharing agreement include certain taxis relate business prior completion ipo create restructure facilitate ipo mead johnson agree indemnify potential tax effect result breach certain representation discuss certain transaction relate acquisition mead johnson stock asset liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense liability represent reasonable provision taxis ultimately expect pay need adjusted time information know discussion income taxis refer item financial statementsnote accounting policiesincome taxis note income taxis contingency normal course business subject contingency legal proceeding claim arise business cover wide range matter include government investigation shareholder lawsuit product environmental liability contractual claim tax matter recognize accrual contingency probable liability incur loss reasonably estimate estimate subject uncertainty difficult predict actual result vary estimate discussion contingency refer item financial statementsnote accounting policiescontingencie note income taxis note legal proceeding contingency product pipeline development program manage portfolio basis early discovery latestage development include balance earlystage latestage program support future growth late stage program phase iii development include investigational compound initial indication additional indication formulation market product spending program represent approximately annual expense year opdivo investigational compound market product represent great expense year latestage development program potentially impact revenue earning year regulatory approval obtain product successfully commercialize follow development market product latestage pipeline product indication date development bms ono announce opdivo designate treatment biliary tract cancer sakigake biliary tract cancer april designation system japan offer priority consultation review bms seattle genetics inc highlight update interim result phase iii study evaluating december opdivo adcetris relapsedrefractory chl interim result previously highlight june bms announce extended followup datum checkmate phase study evaluate opdivo patient june relapse progress chl autologous stem cell transplant chl bms seattle genetics inc expand clinical collaboration evaluate combination opdivo june adcetris brentuximab vedotin pivotal phase iii study relapsedrefractory transplant advanced chl fda approval update indication opdivo treatment adult patient chl april relapse progress autohsct brentuximab vedotin line systemic therapy include autohsct approval japan treatment unresectable advanced recurrent gastric cancer progress september chemotherapy receive alliance partner ono gastric announce result ono phase iii study evaluate opdivo patient previously treat january advanced gastric cancer refractory intolerant standard therapy ono alliance partner conduct study announce checkmate randomize phase iii study evaluate efficacy safety opdivo gbm april patient recurrence gbm meet primary endpoint improve overall survival bevacizumab monotherapy fda approval treatment patient hcc type liver cancer previously treat hcc september sorafenib april approval treatment scchn adult progress platinumbase therapy hnc march approval treatment recurrent metastatic hnc japan receive alliance partner ono announce datum cohort phase iii checkmate study evaluate opdivo treatment hpv june opdivo patient advance cervical vaginal vulvar cancer associate infection hpv fda approval treatment adult pediatric patient msih dmmr mcrc mcrc august progress follow treatment fluoropyrimidine oxaliplatin irinotecan fda approval injection intravenous use adjuvant treatment patient melanoma december involvement lymph nodes metastatic disease undergone complete resection announce ema validate type variation application seek expand current indication october include treatment patient melanoma high risk disease recurrence follow complete surgical resection announce treatment opdivo result significant improvement recurrencefree survival compare september melanoma yervoy patient stage iiibc stage melanoma follow complete surgical resection announce phase iii study evaluate opdivo versus yervoy patient stage iiibc stage july melanoma high risk recurrence follow complete surgical resection meet primary endpoint recurrencefree survival plan interim analysis announce proofofconcept datum phase iiia study opdivo combination bms june investigational antilag therapy patient advance melanoma previously treat antipdpd therapy approval treatment patient previously treat locally advanced unresectable muc type june bladder cancer adult failure platinumcontaine therapy muc fda approval treatment patient previously treat locally advanced metastatic urothelial february carcinoma type bladder cancer announce fda lift partial clinical hold place checkmate clinical study december investigate opdivo base combination patient relapse refractory multiple myeloma announce fda place partial clinical hold checkmate checkmate multiple myeloma clinical study investigate opdivo base combination patient relapse refractory multiple september myeloma partial clinical hold relate risk identify study study antipd agent pembrolizumab patient multiple myeloma announce phase iii study checkmate multinational randomized study evaluate opdivo versus docetaxel previously treat advanced metastatic nsclc stop early meet primary november endpoint demonstrate superior overall survival checkmate multinational phase iii study predominately chinese patient bms submit bla opdivo china food drug administration cfda propose indication previously treat nsclc accept cfda nsclc announce threeyear overall survival datum checkmate checkmate pivotal phase iii september randomize study evaluate opdivo docetaxel patient previously treat metastatic nsclc announce fiveyear overall survival datum study phase study evaluate opdivo april patient previously treat advanced nsclc announce threeyear overall survival update checkmate phase iii study evaluate opdivo opdivo rcc november everolimus previously treat advanced rcc bms clovis oncology inc announce clinical collaboration evaluate combination opdivo rubraca rucaparib pivotal phase iii study advance ovarian cancer triplenegative breast cancer phase study metastatic castrationresistant prostate cancer july announce fda accept company sbla update opdivo dosing include infuse minute week currently approve monotherapy indication fda action date march bms incyte announce company advance clinical development program evaluate april combination opdivo epacadostat phase iii registrational study firstline nsclc spectrum pdl expression firstline hnc announce new datum checkmate phase study evaluate opdivo monotherapy combination crc january yervoy previously treat patient dmmr msih metastatic crc interim datum previously announce june announce efficacy datum checkmate phase study evaluate opdivoyervoy potential june treatment patient melanoma metastatic brain melanoma announce overall survival datum checkmate phase iii study evaluate opdivo april combination yervoy patient previously untreate advanced melanoma announce result ifct map study evaluate opdivo opdivo combine yervoy mpm june previously treat unresectable mpm patient announce pivotal phase iii checkmate study demonstrate superior progressionfree survival combination opdivoyervoy versus chemotherapy firstline nsclc patient high tumor nsclc february mutation burden regardless pdl expression study continue plan assess opdivoyervoy combination coprimary endpoint overall survival patient express pdl announce fda accept company sbla priority review opdivoyervoy treat intermediate poorrisk patient advance rcc fda action date april november announce december result new exploratory analysis pdl expression subgroup phase iii checkmate study evaluate opdivoyervoy standard care sunitinib intermediate poorrisk patient previously untreate advanced metastatic rcc opdivoyervoy announce ema validate type variation application seek expand current indication november opdivoyervoy include treatment intermediate poorrisk patient advance rcc announce checkmate phase iii study evaluate opdivoyervoy versus sunitinib patient previously untreate advanced metastatic rcc meet coprimary endpoint demonstrate superior overall rcc september survival intermediate poorrisk patient combination meet secondary endpoint improve overall survival randomize patient base plan interim analysis independent datum monitor committee recommend study stop early announce topline result checkmate combination opdivoyervoy meet coprimary august endpoint objective response rate favor coprimary endpoint progressionfree survival reach statistical significance bms exelixis inc announce initiation phase iii checkmate study evaluate opdivo combination cabometyx cabozantinib exelixis small molecule inhibitor receptor tyrosine kinase july opdivo yervoy combination cabometyx versus sunitinib patient previously untreate advanced metastatic rcc announce datum evaluate opdivo opdivoyervoy previously treat sclc patient tumor sclc october evaluable tumor mutation burden phase iii checkmate study bms exelixis announce clinical development collaboration evaluate cabometyx opdivo february combination yervoy agreement expect include phase iii study firstline rcc additional study plan bladder cancer hcc potentially tumor type announce result realworld datum analysis humana database treatment eliquis associate significantly low risk strokesystemic embolism low rate major bleed compare warfarin patient age year old nvaf announce datum emanate phase study explore safety efficacy eliquis patient august nvaf undergo cardioversion announce result realworld datum analysis pool large insurance claim database eliquis nvaf treatment eliquis associate low risk strokesystemic embolism low rate major bleeding compare warfarin overall population select highrisk patient sub population announce finding realworld datum analysis medicare database compare risk stroke march systemic embolism rate major bleeding patient nonvalvular atrial fibrillation treat direct oral anticoagulant versus warfarin approval treatment active psa adult response previous diseasemodifying antirheumatic drug therapy include methotrexate inadequate additional systemic therapy psa july psoriatic skin lesion require orencia fda approval active psa adult chronic inflammatory disease affect skin musculoskeletal system fda approval new subcutaneous administration option use patient year age old jia march moderately severely active polyarticular jia announce datum phase study pediatric patient newly diagnose philadelphia december chromosomepositive treat sprycel add chemotherapy regiman fda expand indication sprycel tablet include treatment child philadelphia november chromosomepositive cml chronic phase sprycel announce datum phase study evaluate sprycel imatinibresistant intolerant june cml newly diagnose pediatric patient chronic phase cml announce ema validate group type variationextension application treat child adolescent aged year year chronic phase philadelphia chromosome positive cml include powder oral suspension approval expand indication treatment unresectable metastatic melanoma pediatric january patient year age older announce fda add fiveyear overall survival datum phase iii study october prescribing information yervoy adjuvant treatment fully resect cutaneous melanoma pathologic involvement regional lymph nodes yervoy melanoma fda approval expand indication treatment unresectable metastatic melanoma pediatric july patient announce relapsefree survival result phase iii study evaluate yervoy mgkg yervoy mgkg june patient stage iii resectable stage melanoma high risk recurrence follow complete surgical resection announce fouryear followup datum phase iii study evaluate empliciti plus empliciti multiple myeloma june lenalidomidedexamethasone lenalidomidedexamethasone patient relapsedrefractory multiple myeloma china fda approval daklinza sunvepra regiman treatmentnaive experienced patient infect hepatitis hcv april genotype chronic hcv addition daklinza approve china combination use franchise agent include sofosbuvir adult patient hcv genotype infection bavarian nordic announce independent datum monitor committee determine continuation prostvac prostate cancer september phase iii prospect study prostvac patient metastatic castrationresistant prostate cancer futile special note forwardlooke statement annual report include document incorporate reference write oral statement time time contain certain forwardlooking statement meaning section security act section securities exchange act identify forwardlooke statement fact use word expect anticipate estimate target project guidance intend plan believe word term similar meaning expression connection discussion future operate financial performance identify forwardlooke statement fact relate strictly historical current fact forwardlooke statement base current expectation involve inherent risk uncertainty include factor delay divert change cause actual outcome differ materially current expectation statement likely relate thing goal plan projection financial position result operation cash flow market position product development product approval sale effort expense performance result current anticipate product outcome contingency legal proceeding financial result base current expectation involve inherent risk uncertainty include internal external factor delay divert change year include important factor cautionary statement include annual report particularly item risk factor believe cause actual result differ materially forwardlooke statement believe prudent plan assumption assurance give goal plan set forth forwardlooke statement achieve reader caution place undue reliance statement speak date undertake obligation release publicly revision forwardlooke statement result new information future event item quantitative qualitative disclosure market risk expose market risk result change currency exchange rate interest rate certain derivative financial instrument available costeffective basis hedge underlie economic exposure financial instrument include derivative subject counterparty credit risk consider overall fair value measurement derivative financial instrument trading purpose foreign exchange risk significant amount revenue earning cash flow expose change foreign currency rate primary net foreign currency translation exposure euro japanese yen foreign currency forward contract manage risk primarily arise certain intercompany purchase transaction expose foreign exchange transaction risk arise nonfunctional currency denominate asset liability earning denominate nonus dollar currency foreign currency forward contract offset exposure designate hedge estimate appreciation underlie currency hedge level dollar variable hold constant decrease fair value foreign exchange forward contract million december reduce earning remain life contract expose translation risk nonus dollardenominate net asset nonus dollar borrowing hedge foreign currency exposure net investment certain foreign affiliate designate hedge net investment effective portion foreign exchange gain loss hedge include foreign currency translation component accumulate comprehensive incomeloss net investment decrease equivalent value nonus debt borrowing change remeasurement basis debt subject recognition income change occur additional information refer item financial statementsnote financial instrument fair value measurement interest rate risk use fixedtofloate interest rate swap contract designate fair value hedge provide appropriate balance fix float rate debt estimate increase basis point shortterm longterm interest rate decrease fair value interest rate swap contract million reduce earning remain life contract estimate increase basis point longterm interest rate decrease fair value longterm debt million marketable security subject change fair value result interest rate fluctuation market factor estimate increase basis point interest rate decrease fair value debt investment approximately million credit risk monitor investment counterpartie objective minimize concentration credit risk investment policy invest institution meet high credit quality standard establish limit time maturity investment individual counterparty policy require investment enter corporate financial institution meet high credit quality standard use derivative instrument expose credit risk counterparty fails perform fair value derivative instrument contract positive counterparty fails perform collateral require party derivative asset liability position policy diversify derivative counterpartie mitigate overall risk counterparty default additional information refer item financial statementsnote financial instrument fair value measurement item financial statement supplementary datum bristolmyer squibb company consolidate statement earning dollar million share datum year end december earning net product sale alliance revenue total revenue cost product sell marketing sell administrative research development income net total expense earning income taxis provision income taxis net earning noncontrolle interest net earning attributable bms earning common share basic diluted cash dividend declare common share consolidate statement comprehensive income dollar millions year end december comprehensive income net earning comprehensive incomeloss net taxis reclassification earning derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation total comprehensive incomeloss comprehensive income comprehensive incomeloss attributable noncontrolle interest comprehensive income attributable bms accompany note integral consolidated financial statement bristolmyers squibb company consolidated balance sheet dollar million share share datum december asset current asset cash cash equivalent marketable security receivables inventory prepaid expense total current asset property plant equipment goodwill intangible asset defer income taxis marketable security asset total asset liability current liability shortterm debt obligation account payable accrue liability defer income income taxis payable total current liability defer income income taxis payable pension liability longterm debt total liability commitment contingency equity bristolmyers squibb company shareholder equity prefer stock convertible series par value share authorize million share issue outstanding liquidation value share common stock par value share authorize billion share billion issue capital excess par value stock accumulate comprehensive loss retain earning cost treasury stock million common share million total bristolmyer squibb company shareholder equity noncontrolle interest total equity total liability equity accompany note integral consolidated financial statement bristolmyers squibb company consolidate statement cash flow dollar million year end december cash flow operating activity net earning adjustment reconcile net earning net cash provide operating activity depreciation amortization net defer income taxis stockbase compensation impairment charge pension settlement amortization divestiture gain royalty asset acquisition charge adjustment change operate asset liability receivable inventory account payable deferred income income taxis payable net cash provide operating activity cash flow invest activity sale maturity marketable security purchase marketable security capital expenditure divestiture proceed acquisition payment net cash provide byused investing activity cash flow financing activity shortterm debt obligation net issuance longterm debt repayment longterm debt repurchase common stock dividend net cash financing activity effect exchange rate cash cash equivalent increasedecrease cash cash equivalent cash cash equivalent begin year cash cash equivalent end year accompany note integral consolidated financial statement note accounting policy recently issue accounting standard basis consolidation consolidate financial statement prepare conformity gaap include account bristolmyer squibb company control majorityowned subsidiary certain variable interest entity intercompany balance transaction eliminate material subsequent event evaluate disclose report issuance date refer summary abbreviate term end term document alliance license arrangement assess determine term provide economic control entity require consolidation entity entity control mean majority voting interest refer variable interest entity consolidate bms power direct activity variable interest entity significantly impact economic performance obligation absorb loss right receive benefit potentially significant entity use estimate judgment preparation financial statement require use management estimate judgment assumption significant assumption estimate determine fair value potential impairment intangible asset sale rebate return accrual legal contingency income taxis determine acquisition divestiture business asset pension postretirement benefit actual result differ estimate result reclassification certain prior period amount reclassify conform current period presentation consolidate statement cash flow previously present interest rate swap contract termination issuance common stock separate line item cash flow financing activity present component financing activity reclassification provide concise financial statement presentation additional information disclose note material revenue recognition revenue recognize persuasive evidence arrangement exist sale price fix determinable collectability reasonably assure title substantially risk reward ownership transfer generally time shipment include supply commercial product alliance partner principal end customer sale certain revenue nonus business recognize date receipt customer alliance revenue relate abilify atripla recognize product sell end customer alliance partner royalty recognize thirdparty sale reliably measurable collectability reasonably assure refer note alliance detail alliance revenue reduce time recognition expect sale return discount rebate sale allowance base historical experience update change fact circumstance include impact applicable healthcare legislation revenue defer historical experience product similar therapeutic category similar operational characteristic right return long exist sufficient historical experience estimate sale return develop income taxis provision income taxis include income taxis pay payable current year plus change defer taxis year defer taxis result difference financial tax basis asset liability adjust change tax rate tax law change enact valuation allowance recognize reduce defer tax asset likely tax benefit realize assessment valuation allowance require require significant judgment include longrange forecast future taxable income evaluation tax planning initiative adjustment defer tax valuation allowance earning period assessment tax benefit recognize uncertain tax position likely tax position sustain examination tax authority base technical merit position tax benefit recognize financial statement particular tax position base large benefit likely realize settlement cash cash equivalent cash cash equivalent include bank deposit time deposit commercial paper money market fund cash equivalent consist highly liquid investment original maturity month time purchase recognize cost approximate fair value marketable security investment company marketable security classify availableforsale date purchase report fair value fair value determine base observable market quote valuation model assessment counterparty credit worthiness credit default risk underlie security overall capital market liquidity investment own company account equity method accounting ability exercise significant influence maintain share net income loss equity investment include income net equity investment review impairment assess decline market value investment carry value temporary consider intent ability retain investment period time sufficient allow anticipated recovery market value duration extent market value cost investee financial condition inventory valuation inventory state low average cost market property plant equipment depreciation expenditure addition renewal improvement capitalize cost depreciation compute straightline method base estimate useful life relate asset range year building year machinery equipment fixture impairment longlive asset current fact circumstance periodically evaluate determine carry value depreciable asset hold recoverable circumstance exist estimate undiscounted future cash flow generate longlived asset appropriate grouping asset compare carry value determine impairment exist low level identifiable cash flow asset determine impair loss measure base difference asset fair value carry value estimate asset fair value base quote market price active market available quote market price available estimate fair value base valuation technique unobservable fair value input discount value estimate future cash flow capitalize software eligible cost obtain internal use software capitalize amortize estimate useful life software acquisition business acquire consolidate obtain control fair value asset acquire liability assume recognize date acquisition excess purchase price estimate fair value net asset acquire recognize goodwill business acquisition cost expense incur contingent consideration potential development regulatory approval salesbase milestone salesbase royalty include purchase price business combination exclude asset acquisition amount allocate lead investigational compound asset acquisition expense date acquisition goodwill acquire inprocess research development intangible asset fair value acquire intangible asset typically determine income method utilize level fair value input market participant valuation assume global view consider potential jurisdiction indication base discount aftertax cash flow projection risk adjust estimate probability technical regulatory success iprd finitelive intangible asset include license develop technology right iprd project reach commercialization amortize straightline basis estimate useful life estimate useful life determine consider period asset expect contribute future cash flow goodwill tested annually impairment assess qualitative factor perform quantitative analysis determine likely fair value net asset carry amount example qualitative factor assess include share price financial performance compare budget longterm financial plan macroeconomic industry market condition substantial excess fair value carry value net asset annual impairment test perform prior year relevant factor assess individually aggregate iprd test impairment annual basis frequently event occur circumstance change indicate potential reduction fair value asset carry value impairment charge recognize extent carry value iprd determine exceed fair value finitelive intangible asset test impairment fact circumstance suggest carry value asset recoverable carrying value exceed project undiscounted pretax cash flow intangible asset impairment loss equal excess carrying value estimate fair value discount aftertax cash flow recognize restructure restructuring charge recognize result action streamline operation reduce number facility estimate impact restructuring plan include future termination benefit exit cost require judgment actual result vary estimate contingency loss contingency legal proceeding claim occur government investigation shareholder lawsuit product environmental liability contractual claim tax matter accrual recognize probable liability incur loss reasonably estimate gain contingency include contingent proceed related divestiture recognize realize legal fee expense incurred advertising product promotion cost advertising product promotion cost include marketing sell administrative expense million million million advertising product promotion cost expense incur foreign currency translation foreign subsidiary earning translate dollar average exchange rate net asset foreign subsidiary translate dollar current exchange rate dollar effect arise translate net asset subsidiary change rate recognize oci research development research development cost expense incur clinical study cost accrue service period specify contract adjust necessary base ongoing review level effort cost actually incur research development cost present net reimbursement alliance partner upfront contingent milestone payment asset acquisition investigational compound include research development expense alternative future use cash flow payment license asset acquisition investigational compound include operating activity outlicense proceed payment acquisition ownership interest legal entity include acquisition meet accounting definition business include investing activity divestiture proceed royalty consideration receive subsequent relate sale asset business adjustment reflect operating activity include divestiture gain loss relate royalty research development asset acquisition charge gain loss debt redemption change fair value write option liability recently adopt accounting standard sharebase payment transaction amend guidance sharebase payment transaction adopt quarter net excess tax benefit million recognize prospectively reduction tax expense capital excess par value stock net excess tax benefit present operate cash flow finance cash flow cash payment tax authority connection share withhold statutory tax withholding requirement present finance cash flow operate cash flow change cash flow presentation apply retrospectively increase operate cash flow decrease finance cash flow million million million respectively income tax accounting intraentity transfer asset inventory amend guidance income tax accounting intraentity transfer asset inventory early adopt quarter modify retrospective approach amend guidance require tax consequence transfer recognize period transfer take place net reduction prepay defer tax asset pertain pre internal transfer intellectual property million adjust retain earning cumulative effect accounting change reduce annual tax expense million beginning addition tax consequence additional internal transfer intellectual property occur future include income tax expense transfer amortize subsequent period recently issue accounting standard revenue contract customer amend guidance revenue recognition adopt quarter modify retrospective method cumulative effect change recognize retain earning new guidance refer asc require entity recognize revenue expect entitle transfer promise good service customer replace exist revenue recognition standard gaap step model utilize achieve core principle identify customer contract identify contract performance obligation determine transaction price allocate transaction price performance obligation recognize revenue performance obligation satisfied company assessment new standard impact substantially complete timing recognize revenue expect change typical net product sale customer exist alliance arrangement royalty salebase milestone outlicense arrangement addition timing recognize royalty salesbase milestone form contingent consideration result divestiture business expect change transaction price long require fix determinable certain variable consideration recognize prior occurrence resolution contingent event extent probable significant reversal estimate cumulative revenue occur certain estimate future royalty termination fee license right previously reacquire alliance partner expect recognize contract asset adoption new standard refer sanofi lilly arrangement note alliance result new guidance cumulative effect adjustment revenue income expect low approximately million million respectively compare report previous standard significant change business process system control expect require gain loss derecognition nonfinancial asset amend guidance gain loss derecognition nonfinancial asset adopt quarter modify retrospective method amendment clarify scope asset derecognition guidance add guidance partial sale nonfinancial asset clarifie recognize gain loss transfer nonfinancial asset contract noncustomer amend guidance clarifie certain transaction sale license product right constitute business require account similar asc include potential recognition variable consideration amend guidance result early recognition variable consideration depend fact circumstance transaction presentation net periodic pension postretirement benefit amend guidance require net periodic benefit component define benefit pension postretirement plan service cost record outside income operation income adopt quarter retrospective basis company expect annual cost product sell marketing sell administrative research development expense increase aggregate correspond offset income service cost component include income amount material adjust amount adoption new guidance follow year end december dollar million report adjust report adjust cost product sell marketing sell administrative research development income net definition business amend guidance revise definition business adopt prospectively quarter amendment provide initial screen substantially fair value gross asset acquire disposed concentrated single identifiable asset group similar identifiable asset integrate set asset activity represent business screen meet set include input substantive process significantly contribute ability create output set represent business amendment narrow definition term output require transfer organize work force output exist amend guidance result transaction account asset future impact result operation dependent individual fact circumstance transaction recognition measurement financial asset liability amend guidance recognition measurement presentation disclosure financial instrument adopt prospectively quarter new guidance require fair value adjustment equity security readily determinable fair value currently classify availableforsale report earning new guidance require qualitative impairment assessment equity investment readily determinable fair value base observable price change charge earning impairment exist amend guidance expect materially impact company result operation base current equity investment portfolio accounting hedging activity amend guidance derivative hedge adopt quarter modify retrospective approach amend guidance revise expand item eligible hedge accounting simplifie hedge effectiveness testing change time recognition presentation certain hedge item certain disclosure requirement modify hedging activity prospective basis amend guidance expect materially impact company result operation lease february fasb issue amend guidance lease accounting amend guidance require recognition rightofuse asset lease liability initially measure present value future lease payment lease term long month guidance effective january early adoption permit modify retrospective approach intend elect available practical expedient adoption assessment amend standard remain ongoing include continue implementation leasing software system procure party vendor evaluation potential change enhancement internal control substantially complete lease information datum gather lease datum extraction process believe overall implementation effort remain schedule system readiness remain critical factor ensure successful adoption january undiscounte value lease obligation approximately million december consist primarily facility lease account operating lease initial rightofuse asset lease liability amount balance sheet adoption subject factor include lease portfolio date adoption selection appropriate discount rate determine fix lease component lease renewal period reasonably certain occur amend guidance expect materially impact company result operation recognition right use asset lease liability goodwill impairment testing january fasb issue amend guidance simplifie recognition measurement goodwill impairment loss eliminate step quantitative impairment test result impairment charge require report unit carry exceed fair value allocate goodwill guidance effective prospective basis january early adoption permit interim annual goodwill impairment test perform january amend guidance expect materially impact company result operation financial instrument measurement credit loss june fasb issue amend guidance measurement credit loss financial instrument entity require use forwardlooke estimate loss model availableforsale debt security credit loss recognize allowance reduction amortize cost guidance effective january early adoption permit modify retrospective approach amend guidance expect materially impact company result operation note business segment information bms operate single segment engage discovery development licensing manufacturing marketing distribution sale innovative medicine help patient prevail disease global research development organization supply chain organization responsible discovery development manufacturing supply product regional commercial organization market distribute sell product business support global corporate staff function segment information consistent financial information regularly review chief executive officer purpose evaluate performance allocate resource set incentive compensation target planning forecast future period product sell principally wholesaler less extent directly distributor retailer hospital clinic government agency pharmacie gross revenue large pharmaceutical wholesaler percentage global gross revenue follow mckesson corporation amerisourcebergen corporation cardinal health inc select geographic area information follow revenue property plant equipment dollar millions united states europe rest worlda otherb total include japan represent total revenue respectively revenue include royalty alliancerelate revenue product sell regional commercial organization product revenue composition total revenue follow year end december dollar millions prioritize brand opdivo eliquis orencia sprycel yervoy empliciti establish brands baraclude sustiva franchise reyataz franchise hepatitis franchise brand total revenue net product sale alliance revenues revenues total revenue note alliance bms enter collaboration arrangement party development commercialization certain product arrangement unique nature party active participant operating activity collaboration expose significant risk reward depend commercial success activity bms inlicense intellectual property own party outlicense intellectual property party arrangement typically include research development manufacturing andor commercial activity cover single investigational compound commercial product multiple compound andor product life cycle stage right obligation party global limited geographic region refer collaboration alliance partner alliance partner product sell alliance arrangement certain market include opdivo eliquis orencia sprycel yervoy empliciti sustiva atripla certain brand payment alliance partner account present result operation consider specific nature payment underlie activity payment relate multiple alliance activity include transfer right separate individual unit account standalone value activity occur life arrangement situation arrangement consideration allocate activity right relative sell price basis multiple alliance activity right standalone value combine single unit account common activity bms alliance partner present result operation follow bms principal end customer sale product sale include net product sale bms alliance partner principal end customer sale bms contractual share thirdparty sale andor royalty income include alliance revenue sale commercial product consider bms ongoing major central operation refer revenue recognition include note accounting policy information recognition criterion amount payable bms alliance partner principal end customer sale supply commercial product include alliance revenue sale commercial product consider bms ongoing major central operation profit share royalty salesbase fee payable bms alliance partner include cost product sell incur cost reimbursement party recognize incur include cost product sell marketing sell administrative expense research development expense base underlying nature relate activity subject reimbursement upfront contingent development approval milestone payable bms alliance partner investigational compound commercial product defer amortize expect period bms copromotion obligation market exclusivity period period relate compound product expect contribute future cash flow amortization present consistent nature payment arrangement example amount receive investigational compound present income net activity perform time relate sale commercial product bmss ongoing major central operation amount receive commercial product present alliance revenue sale commercial product consider bmss ongoing major central operation astrazeneca alliance pertain amylin product discussion specific astrazeneca alliance disclosure upfront contingent approval milestone payable bms alliance partner commercial product capitalize amortize short contractual term period relate product expect contribute future cash flow amortization include cost product sell upfront contingent milestone payable bms alliance partner prior regulatory approval expense incur include research development expense royalty contingent consideration payable bms alliance partner relate divestiture business include income earn equity net income affiliate include income net payment bms alliance partner present cash flow operating activity describe select financial information pertain alliance follow include net product sale bms principal thirdparty customer sale product subject alliance expense summarize include amount attribute activity product alliance payment alliance partner relate amortization payment defer capitalize year end december dollar millions revenue alliance net product sale alliance revenue total revenue payment tofrom alliance partner cost product sell marketing sell administrative research development income net noncontrolle interest pretax select alliance balance sheet information december dollar million receivable alliance partner account payable alliance partner defer income alliancesa include unamortized upfront milestone licensing proceed revenue deferral attribute atripla undelivered element diabete business divestiture proceed amortization defer income primarily relate alliance million million million upfront payment new licensing alliance agreement include option license acquire related asset charge research development expense million million million specific information pertain significant alliance discuss include nature purpose significant right obligation party specific accounting policy election income statement classification amount attributable payment party pfizer bms pfizer jointly develop commercialize eliquis anticoagulant discover bms pfizer fund development cost depend study profit loss share equally global basis certain country pfizer commercialize eliquis pay bms sale base fee coexclusive license right grant pfizer exchange upfront payment potential milestone payment party assume certain obligation actively participate joint executive committee operating committee joint responsibility research development distribution sale marketing activity alliance resource infrastructure bms manufacture product alliance principal end customer product sale significant country europe canada australia china japan south korea bms transfer commercialization right pfizer certain small country order simplify operation transfer country bms supply product pfizer cost plus percentage net sale price endcustomer company determine right transfer pfizer standalone value right sell separately bms party pfizer receive benefit deliver right fulfillment ongoing obligation bms alliance agreement include exclusive supply arrangement global alliance treat single unit accounting upfront proceed subsequent contingent milestone proceed amortize expect period bms copromotion obligation market exclusivity period bms receive million nonrefundable upfront milestone licensing payment relate eliquis december amortization eliquis defer income include income eliquis commercial product commencement alliance summarize financial information relate alliance follow year end december dollar millions revenue pfizer alliance net product sale alliance revenue total revenue payment tofrom pfizer cost product sell profit sharing income net amortization defer income select alliance balance sheet information december dollar millions defer income gilead bms gilead form joint venture canada joint venture europe develop commercialize combination product name atripla combine bms sustiva gilead truvada joint venture consolidate gilead december gilead terminate bms participation canada joint venture follow launch generic version sustiva thirdparty result deferred income alliance receivables attribute sustiva product hold joint venture december reduce million reflect posttermination sell price addition bms entitle fee equal atripla net sale multiply ratio difference average net selling price atripla truvada atripla average net selling price fee reduce atripla net sale multiply ratio describe bms continue supply sustiva cost plus markup gilead threeyear period party elect terminate supply arrangement prior termination bms participation joint venture party actively participate joint executive committee operating committee direct oversight activity joint venture joint venture purchase sustiva truvada api bulk form party complete finish atripla joint venture distribute atripla principal end customer product sale bms record bulk efavirenz component atripla alliance revenue base relative ratio average respective net selling price truvada sustiva alliance revenue related alliance receivable recognize atripla sell thirdparty customer joint venture europe account bms continue operate similar manner describe gilead distribute atripla principal end customer product sale party long coordinate joint promotional activity european joint venture continue party terminate arrangement patent expire allow market exclusivity atripla summarize financial information relate alliance follow year end december dollar million revenue gilead alliance alliance revenues equity net loss affiliate select alliance balance sheet information december dollar millions defer income otsuka bms otsuka copromote sprycel japan oncology territory party actively participate governance committee bms control decision make bms responsible development manufacture product principal end customer product sale ixempra ixabepilone include alliance prior bms divestiture business fee pay otsuka base follow percentage combine annual net sale sprycel ixempra oncology territory include post divestiture ixempra sale net sale million million million million million million billion excess billion bm worldwide commercialization agreement otsuka codevelop copromote abilify exclude certain asian country portion agreement expire april portion expire june country exclusive right sell abilify expiration occur countrybycountry basis expiration canada january party actively participate joint executive governance operate committee otsuka responsible provide sale force effort bms responsible certain operating expense annual limit bms purchase api otsuka complete manufacture product subsequent sale thirdparty customer certain country bms provide service include distribution customer management pharmacovigilance bms principal end customer product sale exclusive distributor exclusive right sell abilify otsuka principal end customer product sale alliance revenue record bms share net sale thirdparty customer abilify ship risk reward ownership transfer thirdparty customer summarize financial information relate alliance follow year end december dollar million revenue otsuka alliance net product sale alliance revenue total revenue payment tofrom otsuka cost product sell oncology fee royalty cost product supply lilly bms commercialization agreement lilly lillys subsidiary imclone codevelopment promotion erbitux canada japan party actively participate joint executive committee operating committee share responsibility research development resource infrastructure lilly manufacture bulk requirement erbitux facility filling finish perform party bms oversight responsibility bm exclusive distribution right north america responsible promotional effort north america lilly right copromote expense bms principal end customer product sale north america pay lilly distribution fee erbitux net sale north america plus share certain royalty pay lilly bmss right obligation respect commercialization erbitux north america expired september october bms transfer right erbitux north america lilly exchange salesbase royalty describe transfer right include limited commercialization manufacturing responsibility transaction account business divestiture result noncash charge million intangible asset directly relate business allocation goodwill bms receive royalty september include income earn royalty rate applicable north america erbitux net sale million million million million plus net sale excess amount respective year royalty earn million million million bms share right erbitux japan agreement lilly merck kgaa receive pretax profit merck kgaas net sale erbitux japan share equally lilly bm transfer cocommercialization right japan merck kgaa exchange sale base royalty include income earn royalty earn million million million result adoption asc quarter estimate future royalty result transfer right merck kgaa record cumulative effect adjustment retain earning subsequent change estimate record income net summarize financial information relate alliance follow year end december dollar millions revenue lilly alliance net product sale alliance revenue total revenue cost product sell income net royalty divestiture loss astrazeneca prior diabetes business divestiture discuss bms alliance astrazeneca consist worldwide codevelopment commercialization agreement cover onglyza relate combination product sell name farxiga relate combination product begin august bms acquisition amylin amylin portfolio product include bydureon byetta symlin myalept certain asset own amylin include manufacturing facility locate west chester ohio february bms astrazeneca terminate alliance agreement bms sell astrazeneca substantially diabete business comprise alliance divestiture include share amylin result transfer ohio manufacturing facility intellectual property relate onglyza farxiga include bms interest outlicensing agreement onglyza japan purchase bmss manufacturing facility locate mount vernon indiana substantially employee dedicated diabetes business transfer astrazeneca bms astrazeneca enter agreement connection sale include supply agreement development agreement transitional service agreement agreement bms obligate supply certain product perform ongoing development activity certain clinical study program provide transitional service account financial service customer service distribution regulatory development information technology certain administrative service period order facilitate orderly transfer business operation consideration transaction include billion payment close contingent regulatory salesbase milestone payment billion include million relate approval milestone million relate salesbased milestone payable royalty payment base net sale payment million certain asset transfer astrazeneca astrazeneca pay bms require product supply price approximating product cost negotiate transitional service fee royalty rate net sale follow onglyza farxiga worldwide net sale million onglyza farxiga worldwide net sale million amylin product net sale stock asset purchase agreement contain multiple element deliver subsequent closing transaction include china diabete business transfer mount vernon indiana manufacturing facility transfer activity development supply agreement element determine standalone value result portion consideration receive closing allocate undelivered element relative selling price method determine well estimate selling price element remain consideration include calculation gain sale diabete business contingent milestone royalty payment similarly allocate underlie element amount determined payable bms amount allocate sale business immediately recognize result operation amount allocate element recognize result operation extent element deliver consideration million receive transfer mount vernon indiana manufacturing facility relate inventory result gain million amount allocate deliver element contingent consideration million receive astrazeneca achievement regulatory approval milestone result additional gain consideration allocate development supply agreement amortize applicable service period amortization defer income attribute development agreement end december include income sale service consider bmss ongoing major central operation amortization defer income attribute supply agreement end december record alliance revenues revenues attribute supply agreement include alliance revenue consideration transaction present cash flow purpose base allocation process describe invest activity attribute sale business relate asset operating activity attribute transitional service supply arrangement development agreement september bm transfer percentage future royalty right amylin net product sale cppib transfer right represent approximately potential future royalty bms entitle exchange transfer bms receive additional tieredbase royalty amylin net product sale cppib royalty present income million million november bm transfer percentage future royalty right portion onglyza farxiga net product sale royalty pharma transfer right represent approximately potential future royalty bms entitle product exchange transfer bms receive additional tieredbase royalty onglyza farxiga net product sale royalty pharma present income earn summarize financial information relate astrazeneca alliance follow year end december dollar millions revenue astrazeneca alliance net product sale alliance revenue total revenues income net amortization defer income royalty transitional service divestiture gain select alliance cash flow information defer income divestiture proceed select alliance balance sheet information december dollar millions defer income service perform astrazeneca sanofi bms sanofi codevelopment cocommercialization agreement plavix avaproavalide effective january sanofi assume essentially worldwide operation alliance exception plavix puerto rico bms operating partner control interest exchange right transfer sanofi bms receive quarterly royalty january december terminal payment sanofi million end result adoption asc future royalty long record alliance revenue record cumulative effect adjustment quarter correspond contract asset addition portion terminal payment record cumulative effect adjustment quarter correspond contract asset royalty receive sanofi territory cover americas australia optout market development royalty present alliance revenues million million million royalty attribute territory cover europe asia continue earn territory partnership include equity net income affiliate alliance revenue attribute supply irbesartan api sanofi million summarize financial information relate alliance follow year end december dollar millions revenue sanofi alliance net product sale alliance revenue total revenue payment tofrom sanofi equity net income affiliate noncontrolle interest pretax follow summarize financial information interest partnership sanofi territory cover europe asia consolidated account equity method year end december dollar million net sale gross profit net income ono bms principal end customer product sale exclusive right develop manufacture commercialize opdivo worldwide japan south korea taiwan ono entitle receive royalty north america territory exclude country list subject customary adjustment bms ono jointly develop commercialize opdivo yervoy bms investigational compound japan south korea taiwan bms responsible supply product profit loss development cost share equally combination therapy involve compound party share activity involve party compound bms ono jointly develop commercialize orencia japan bms responsible order fulfillment distribution intravenous formulation ono responsible subcutaneous formulation formulation jointly promote party assign customer account bms responsible product supply copromotion fee pay sale partys assign customer ono grant bms exclusive license development commercialization ono onos prostaglandin receptor antagonist bms acquire worldwide right japan south korea taiwan add exist collaboration china asean country ono retain exclusive right bms pay million ono include expense ono eligible receive subsequent clinical regulatory salesbase milestone payment million royalty country bms exclusive licensing right summarize financial information relate alliance follow year end december dollar millions revenue ono alliance net product sale alliance revenue total revenues abbvie bms grant exclusive global right codevelop commercialize empliciti humanize monoclonal antibody treatment multiple myeloma pdl biopharma inc abbvie abbvie currently participate joint development commercialization committee bms final decision make authority party jointly develop product abbvie fund global development cost bms solely responsible supply distribution sale marketing activity principal end customer product sale abbvie share profit loss pay tiere royalty outside bms pay abbvie million certain regulatory milestone event include million approval milestone december abbvie entitle receive additional million certain regulatory event occur million certain sale threshold achieve agreement terminate immediately bm party material breach subsequent notice period summarize financial information relate alliance follow year end december dollar millions revenues abbvie alliance net product sale payment tofrom abbvie cost product sell profit sharing fstar alpha october bms acquire exclusive option purchase fstar alpha lead asset antiher antibody fragment development treatment breast gastric cancer welldefine population herpositive patient bms discontinue development exercise option result iprd charge million include expense attribute noncontrolle interest promedior september bms purchase warrant give bms exclusive right acquire promedior biotechnology company lead asset prm develop treatment ipf warrant exercisable delivery phase datum follow ipf phase clinical study direct promedior upfront payment allocate warrant million include expense remain million million upfront payment allocate promedior obligation complete phase study amortize expect period phase study allocation determine level input bms obligate pay additional million plus additional aggregate consideration million contingent development regulatory approval milestone payment europe exercise warrant prime november bms prime enter exclusive worldwide licensing collaboration agreement development commercialization prime csfr antibody program include cabiralizumab currently phase development indications phase development pvn prime responsible completion phase study combine cabiralizumab opdivo potential treatment variety cancer bms responsible development manufacturing commercialization activity prime conduct certain study cost develop cabiralizumab pvns combination internal oncology pipeline asset prime retain option copromote agreement replace previous clinical collaboration agreement party consideration licensing right bms upfront payment million include expense bms commit pay billion achievement contingent development regulatory milestone future royalty product approve commercialize reckitt bms transfer reckitt right sell distribute market otc brand sell primarily mexico brazil bms receive royalty net sale product exclusively supply certain product reckitt pursuant supply agreement cost plus markup certain limited asset include marketing authorization certain employee directly attribute business transfer reckitt start alliance period bms retain ownership asset relate business include trademark cover product bms grant reckitt option acquire trademark inventory certain asset exclusively relate product end alliance period price determine primarily base multiple sale april alliance modify provide option reckitt purchase bms manufacturing facility locate mexico primarily dedicated product include alliance related employee july reckitt notify bms exercise option bms sell business million nonrefundable upfront proceed million receive bms allocate unit account include right transfer reckitt fair value option purchase remain asset good estimate sell price element consider market factor market factor include analysis estimate excess fair value business potential purchase price option exercise fair value option determine level input include liability bms recognize income million decrease fair value option zero strengthen dollar local currency allocate right transfer reckitt amortize alliance revenue contractual term summarize financial information relate alliance follow year end december dollar millions revenues reckitt alliance alliance revenues income net divestiture gain select alliance cash flow information change operate asset liability divestiture proceed medicine company february bms transfer medicine company right sell distribute market recothrom global basis year certain employee directly attribute business certain asset transfer medicine company start alliance period include biologic license application relate regulatory asset bms retain asset relate recothrom include patent trademark inventory bms grant medicine company option acquire patent trademark inventory certain asset exclusively relate recothrom price determine base multiple sale plus cost remain inventory hold bms time medicine company exercise option february acquire business million result million divestiture gain valeant october bms transfer pharmaswiss whollyowne subsidiary valeant right sell distribute market certain mature brand product europe december bms grant valeant option acquire trademark intellectual property exclusively relate product price determine base multiple sale valeant exercise option january acquire business million result million divestiture gain note acquisition divestiture license arrangement acquisition acquisition evaluate determine business asset group asset follow transaction account asset acquisition determined business term define asc business combination primarily significant process acquire result amount allocate lead investigational compound expense capitalize consideration transaction allocate follow contingent dollar millions year upfront payment expense defer tax assetsa consideration ifmb cormorant padlock cardioxyl flexusc relate net operating loss tax credit carryforward include million certain negotiation right collaborate license acquire nlrp antagonist program newly form entity establish shareholder ifm include million acquisition cost ifm bms acquire outstanding share ifm private biotechnology company focus develop therapy modulate novel target innate immune system treat cancer autoimmunity inflammatory disease acquisition provide bms right ifm preclinical sting nlrp agonist program focus enhance innate immune response treat cancer contingent consideration include development regulatory salesbase milestone payment bms pay million additional contingent milestone subsequent product select ifm preclinical sting nlrp agonist program include contingent consideration table cormorant bms acquire outstanding share cormorant private pharmaceutical company focus development therapies cancer rare disease acquisition provide bms right cormorant lead candidate humaxil phase iii monoclonal antibody represent potentially complementary immunooncology mechanism action tcell direct antibodie costimulatory molecule contingent consideration include development regulatory milestone payment padlock bms acquire outstanding share padlock private biotechnology company dedicate create new medicine treat destructive autoimmune disease acquisition provide bms right padlock pad inhibitor discovery program focus development potentially transformational treatment approach patient rheumatoid arthritis padlock pad discovery program additional utility treat systemic lupus erythematosus autoimmune disease contingent consideration include development regulatory milestone payment cardioxyl bms acquire outstanding share cardioxyl private biotechnology company focus discovery development novel therapeutic agent cardiovascular disease acquisition provide bms right cxl nitroxyl prodrug phase development acute decompensate heart failure contingent consideration include development regulatory salesbase milestone payment million include expense follow commencement phase clinical study flexus bms acquire outstanding share flexus private biotechnology company focus discovery development novel anticancer therapeutic acquisition provide bms right preclinical small molecule idoinhibitor target immunotherapy addition bms acquire flexus idotdo discovery program include idoselective idotdo dual tdoselective compound contingent consideration include development regulatory milestone payment million million include expense respectively follow commencement phase phase phase iii clinical study divestiture proceedsa divestiture gain loss royalty income dollar million investigational hiv medicine otc brand reckitt diabete erbitux recothrom mature brand product valeant ixempra include royalty receive subsequent relate sale asset business biotek bms sell small molecule active pharmaceutical ingredient manufacturing operation sword ireland biotek approximately million subject certain adjustment initial proceed million receive quarter transaction account sale business divestiture include transfer facility majority employee site inventory certain thirdparty contract manufacturing obligation asset reduce estimate relative fair value consider purchase price result impairment charge million include cost product sell biotek provide certain manufacturing service bms viiv healthcare bms sell investigational hiv medicine business consist number program different stage discovery development viiv healthcare bm receive million entitle receive viiv healthcare contingent development regulatory milestone payment billion salesbase milestone payment billion future tiere royalty bms earn transitional fee million million certain service respectively divestiture refer note alliance discussion divestiture transaction reckitt lilly medicines company valeant astrazeneca revenue pretax earning relate divestiture material exclude divestiture gain impairment charge asset heldforsale bms agree sell facility wallingford connecticut transaction expect close quarter account sale asset asset account heldforsale december reduce estimate relative fair value result impairment charge million include expense licensing arrangement halozyme bms halozyme enter global collaboration license agreement develop subcutaneously administer bms medicine halozyme enhanze drugdelivery technology technology allow rapid delivery large volume injectable medication subcutaneous delivery bms pay million halozyme access technology include expense bms designate multiple target include develop enhanze technology option select additional target year effective date maximum target bms pay additional million achieve contingent development regulatory salesbase milestone nominate collaboration target additional milestone payment combination product future royalty sale product enhanze technology cytomx bms expand strategic collaboration cytomx discover novel therapy cytomxs proprietary probody platform original collaboration discover develop commercialize probody therapeutic bms select oncology target include ctla pursuant expand agreement cytomx grant bms exclusive worldwide right develop commercialize probody therapeutic additional target bms pay cytomx million right initial target expense prior bms pay million cytomx access additional target include expense bms reimburse cytomx certain research cost collaboration period pay contingent development regulatory sale base milestone million achieve collaboration target future royalty biogen bms outlicense biogen exclusive right develop commercialize bms antietau compound development progressive supranuclear palsy biogen pay million bms include income bms entitle contingent development regulatory sale base milestone payment million achieve future royalty bms originally acquire right compound acquisition ipierian biogen assume bmss remain obligation stockholder ipierian roche bms outlicense roche exclusive right develop commercialize bms antimyostatin adnectin development duchenne muscular dystrophy roche pay million bms include income bms entitle contingent development regulatory milestone payment million achieve future royalty note income net income net include year end december dollar million interest expense investment income provision restructure litigation settlement equity net income affiliate divestiture gain royalty license income transition service fee pension charge intangible asset impairment equity investment impairment write option adjustment loss debt redemption income net litigation settlement include bms share patentinfringement settlement million relate merck antibody keytruda million contractual dispute relate license royalty licensing income include upfront licensing fee million biogen roche transition service fee primarily relate divestiture diabete investigational hiv medicine business write option adjustment includes change fair value write option liability attribute reckitt alliance include unrealized foreign exchange loss million result remeasurement bolivardenominate cash monetary balance bmss whollyowne subsidiary venezuela december note restructuring october company announce restructure plan evolve streamline operating model expect incur charge connection employee workforce reduction early site exit majority charge expect incur range billion billion consist employee termination benefit cost contract termination cost accelerate depreciation impairment charge site exit cost cash outlay connection action expect approximately total charge charge approximately million recognize action announcement include impairment charge small molecule manufacturing operation sword ireland restructuring charge recognize meet certain criterion include finalization commit plan reliable estimate discussion local work council certain market restructure charge addition action recognize prior primarily relate specialty care transformation initiative design create simplify organization function geographic market addition accelerate depreciation charge incur connection expect early exit small molecule manufacturing site cruiserath ireland facility wallingford connecticut refer note acquisition divestiture license arrangement information employee workforce reduction approximately follow table summarize charge activity relate restructuring action year end december dollar million employee termination cost termination cost provision restructuring accelerate depreciation asset impairment shutdown cost total charge year end december dollar million cost product sell marketing sell administrative research development income net total charge year end december dollar million liability january charge change estimate provision restructure foreign currency translation spending liability december note income taxis provisionbenefit income taxis consist year end december dollar millions current nonus total current defer nonus total defer total provision effective tax rate reconciliation effective taxbenefit rate statutory federal income tax rate earning income taxis dollar million earningsloss income taxis nonus total statutory rate deem repatriation transition tax defer tax remeasurement foreign tax effect certain operation ireland puerto rico switzerland federal valuation allowance release federal state foreign contingent tax matter federal research base credit goodwill allocate divestiture brand prescription drug fee nondeductible charge puerto rico excise tax domestic manufacturing deduction state local taxis net valuation allowance foreign new tax reform legislation enact december know tax cut job act act act move worldwide tax system quasiterritorial tax system comprise broad complex change tax code include limited reduce tax rate add deem repatriation transition tax certain foreign earning profit generally eliminate federal income taxis dividend foreign subsidiary include certain income control foreign company taxable income create new minimum tax refer base erosion antiabuse income tax limit certain researchbase credit eliminate domestic manufacturing deduction aspect act effective additional tax expense billion recognize fourth quarter enactment act additional expense include billion onetime deem repatriation transition tax previously untaxe post foreign earning profit include related tax reserve earning effectively tax rate extent specify foreign corporation hold cash certain asset rate remain earning profit remain additional tax expense include adjustment measure net defer tax asset new tax rate accounting reduction defer tax asset tax rate complete tax charge deem repatriation tax incomplete record provisional able reasonable estimate tax provisional amount change complete finalize untaxed post foreign earning profit relate cash certain eligible asset specify foreign corporation provisional amount change additional guidance relevant tax code release earning certain manufacturing operation low tax jurisdiction switzerland ireland puerto rico indefinitely reinveste prior enactment act bms operate favorable tax grant puerto rico schedule expire prior result transition tax act company long indefinitely reinveste respect undistribute earning foreign subsidiary provide defer tax liability foreign state income withholding tax apply company remain indefinitely reinveste respect financial statement basis excess tax basis foreign subsidiary determination defer tax liability respect basis difference practicable valuation allowance attribute capital loss carryforward release follow divestiture recothrom ixempra mature brand goodwill allocate business divestiture brand prescription drug fee deductible tax purpose charge primarily acquisition relate milestone payment shareholder deductible tax purpose include flexus cardioxyl ifm flexus padlock cormorant flexus cardioxyl puerto rico impose excise tax gross company purchase price good sell manufacturer puerto rico excise tax recognize cost product sell intraentity sale occur income tax purpose excise tax deductible result foreign tax credit generally recognize provision income taxis excise tax incur increase manufacturing activity opdivo result high domestic manufacturing deduction compare defer taxis valuation allowance component current noncurrent defer income tax assetsliabilitie follow december dollar millions defer tax asset foreign net operating loss carryforward state net operating loss credit carryforward federal net operating loss credit carryforward defer income milestone payment license fee pension postretirement benefit intercompany profit inventory item foreign defer tax asset sharebase compensation internal transfer intellectual property total defer tax asset valuation allowance defer tax asset net valuation allowance defer tax liability depreciation acquire intangible asset goodwill total defer tax liability defer tax asset net recognize deferred income taxis noncurrent income taxis payable noncurrent total adoption amend guidance intraentity transfer asset inventory result net reduction prepay defer tax asset pertain pre internal transfer intellectual property million adjust retain earning cumulative effect accounting change additionally amend guidance sharebase payment transaction adopt net excess tax benefit million recognize prospectively reduction tax expense capital excess par value stock tax benefit realize result stock relate compensation credit capital excess par value stock million million adoption amend guidance item reduce effective tax rate year end december refer note basis presentation recently issue accounting standard information federal net operating loss carryforward million december carryforward acquire result certain acquisition subject limitation section internal revenue code net operating loss carryforward expire vary amount begin foreign state net operating loss carryforward expire vary amount begin certain amount unlimited life december valuation allowance million establish follow item million primarily foreign net operating loss tax credit carryforward million state defer tax asset include net operating loss tax credit carryforward million federal net operating loss carryforward million federal defer tax asset change valuation allowance follow year end december dollar million balance begin year provision utilization foreign currency translation acquisition non rate change balance end year income tax payment million billion million business conduct country world subject tax numerous jurisdiction significant number tax return file subject examination federal state local tax authority tax examination complex tax authority disagree treatment item report require year resolve liability establish possible assessment tax authority result know tax exposure include limited transfer pricing matter tax credit deductibility certain expense deem repatriation transition tax liability represent reasonable provision taxis ultimately expect pay need adjusted time information know effect change estimate related contingent tax liability include effective tax rate reconciliation reconciliation begin end gross unrecognized tax benefit follow year end december dollar million balance begin year gross addition tax position relate current year gross addition tax position relate prior year gross addition tax position assume acquisition gross reduction tax position relate prior year settlement reduction tax position relate lapse statute cumulative translation adjustment balance end year additional information unrecognized tax benefit follow year end december dollar millions unrecognized tax benefit recognize impact effective tax rate accrue interest accrue penalty accrue interest penalty payable unrecognized tax benefit include current noncurrent income taxis payable interest penalty relate unrecognized tax benefit include income tax expense bms currently examination number tax authority propose consider propose material adjustment tax position issue transfer price certain tax credit deductibility certain expense reasonably possible new issue raise tax authority require adjustment unrecognized tax benefit estimate adjustment reasonably time reasonably possible total unrecognized tax benefit december decrease range approximately million million month result settlement certain tax audits event expect change unrecognized tax benefit result payment additional taxis adjustment certain defer taxis andor recognition tax benefit reasonably possible new issue raise tax authority increase unrecognized tax benefit estimate increase reasonably time bms believe adequately provide open tax year tax jurisdiction follow summary major tax jurisdiction tax authority assert additional taxis base tax year currently audit subsequent year likely audit canada france germany italy mexico note earning share year end december amount million share datum net earning attributable bms basic diluted eps calculation weightedaverage common share outstanding basic incremental share attributable sharebased compensation plan weightedaverage common share outstanding diluted earning share basic earning share dilute note financial instrument fair value measurement financial instrument include cash cash equivalent marketable security account receivable payable debt instrument derivative change exchange rate interest rate create exposure market risk certain derivative financial instrument available costeffective basis hedge underlie economic exposure instrument qualify cash flow net investment fair value hedge meet certain criterion include effectiveness offset hedge exposure change fair value derivative qualify hedge accounting recognize earning occur derivative financial instrument trading purpose financial instrument subject counterparty credit risk consider overall fair value measurement counterparty credit risk monitor ongoing basis mitigate limiting amount outstanding individual counterparty utilize conventional derivative financial instrument enter agreement counterpartie meet high credit quality standard consolidate financial statement materially impact counterparty fail perform accord term agreement collateral require party derivative asset liability position term agreement fair value measurement fair value financial instrument classify follow category level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input level input utilize observable price similar instrument quote price identical similar instrument nonactive market additionally certain corporate debt security utilize thirdparty matrix pricing model significant input corroborate market datum substantially term asset equity fix income fund primarily invest publicly trade security value respective net asset value underlie investment level derivative instrument value libor yield curve credit valuation adjustment observable forward foreign exchange rate report date valuation derivative contract fluctuate considerably volatility underlie foreign currency underlie interest rate drive market condition duration contract level unobservable input little market datum available level financial asset liability december financial asset liability measure fair value recur basis summarize december december dollar million level level level level cash cash equivalent money market security marketable security certificate deposit commercial paper corporate debt security equity fund fix income fund derivative asset equity investment derivative liability equity investment measure fair value year end exclude table limit partnership equity method investment million million equity investment readily determinable fair value million million amount include asset availableforsale security follow table summarize availableforsale security december december gross unrealized gross unrealized amortize amortize dollar million cost gain loss fair value cost gain loss fair value certificate deposit commercial paper corporate debt security equity investment financial asset measure fair value option equity fix income fundsa total december december dollars million current marketable security noncurrent marketable securitiesb assetsc total fair value option financial asset elect investment equity fix income fund include current marketable security change fair value significant ball noncurrent marketable security mature year december cinclude equity investment qualifying hedge nonqualifye derivative follow summarize fair value outstanding derivative december december asseta liabilityb asseta liabilityb dollar million notional fair value notional fair value notional fair value notional fair value derivative designate hedge instrument interest rate swap contract forward start interest rate swap contract foreign currency forward contract derivative designate hedge instrument foreign currency forward contract ainclude prepay expense asset binclude accrue liability pension liability cash flow hedge foreign currency forward contract hedge certain forecast intercompany inventory purchase transaction certain foreign currency transaction effective portion change fair value contract designate cash flow hedge temporarily report accumulate comprehensive loss include earning hedge item affect earning net gain foreign currency forward contract expect reclassify net earning primarily include cost product sell year notional outstanding foreign currency forward contract primarily attribute euro million japanese yen million december bm enter million forward start interest rate swap contract mature march hedge variability probable forecast interest expense associate potential future issuance debt bms terminate forward start interest rate swap contract proceed relate gain material contract designate cash flow hedge effective portion fair value change include comprehensive income earning impact relate discontinued cash flow hedge hedge ineffectiveness significant period present cash flow hedge accounting discontinue forecast transaction long probable occur day originally forecast date hedge long effective assessment determine derivative designate qualifying hedge highly effective offset change cash flow hedge item perform inception quarterly basis net investment hedge nonus dollar borrowing million million december designate hedge foreign currency exposure net investment certain foreign affiliate borrowing designate net investment hedge recognize long term debt effective portion foreign exchange loss remeasurement euro debt million gain million million respectively record foreign currency translation component accumulate comprehensive loss relate offset longterm debt fair value hedge fixedtofloate interest rate swap contract designate fair value hedge interest rate risk management strategy create appropriate balance fix float rate debt contract underlie debt hedge benchmark risk record fair value effective interest rate contract onemonth libor december plus interest rate spread range underlying swap terminate prior maturity fair value basis adjustment underlie debt instrument amortize reduction interest expense remain life debt notional fixedtofloate interest rate swap contract execute million notional fixedtofloate interest rate swap contract terminate million million generating proceed million million include accrue interest additional contract terminate connection debt redemption debt obligation shortterm debt obligation include december dollar millions commercial paper nonus shortterm borrowing current portion longterm debt total average commercial paper outstanding million weightedaverage interest rate maximum commercial paper outstanding billion million outstanding borrowing december commercial paper borrowing longterm debt current portion longterm debt include december dollar million principal value note note note note note note euro note note note euro note note note note note note mature subtotal adjustment principal value fair value interest rate swap contract unamortize basis adjustment swap termination unamortized bond discount issuance cost total current portion longterm debt longterm debt fair value longterm debt billion billion december respectively estimate level input base quote market price similar debt instrument fair value shortterm borrowing approximate carry value short maturity debt instrument senior unsecured note issue register public offering notes rank equally right payment bms exist future senior unsecured indebtedness redeemable time predetermine redemption price bms terminate forward start interest rate swap contract enter result unrealized loss comprehensive income follow table summarize issuance longterm debt obligation amount million dollar euro dollar principal value note euro note note euro note total proceed net discount defer loan issuance cost forward start interest rate swap contract terminate notional realize gain unrealized loss bms repay million note maturity follow summarize debt redemption activity dollar million principal carry value debt redemption price notional interest rate swap contract terminate interest rate swap termination payment loss debt redemptiona ainclude acceleration debt issuance cost loss interest rate lock contract relate fee interest payment million million million net amount receive interest rate swap contract currently separate revolve credit facility total billion syndicate lender facility provide customary term condition financial covenant day billion facility expire march billion facility extend october july billion fiveyear facility extendable annually year anniversary date consent lender borrowing outstanding revolve credit facility december available financial guarantee provide form standby letter credit performance bond million december standby letter credit issue financial institution support guarantee obligation performance bond issue support range ongoing operating activity include sale product hospital foreign ministry health bond custom duty value add tax guarantee relate miscellaneous legal action significant majority outstanding financial guarantee expire year expect fund note receivable december dollar million trade receivable chargeback cash discount bad debt allowance net trade receivables alliance receivables prepay refundable income taxis royaltie vat receivables nonus receivables sell nonrecourse basis million million million aggregate receivable pharmaceutical wholesaler represent total trade receivables december respectively change allowance bad debt chargeback cash discount follow year end december dollar million balance begin year provision utilization balance end year note inventory december dollar million finished good work process raw packaging material inventory inventory asset asset include inventory expect remain hand year period note property plant equipment lease december dollar million land building machinery equipment fixture construction progress gross property plant equipment accumulate depreciation property plant equipment depreciation expense million million million gross property plant equipment million million net accumulate depreciation reclassify asset heldforsale december result pende sale facility wallingford connecticut refer note acquisition divestiture license arrangement additional information annual minimum rental commitment noncancelable operating lease primarily real estate motor vehicle approximately million year aggregate million operate lease expense approximately million million million sublease income capital lease obligation material period present note goodwill intangible asset december estimate dollar million useful life goodwill intangible asset license year develop technology right year capitalize software year iprd gross intangible asset accumulate amortization total intangible asset amortization expense intangible asset million million million future annual amortization expense intangible asset expect approximately million million million million million intangible asset impairment charge million million million million iprd charge recognize attribute noncontrolle interest bms decline exercise option purchase fstar alpha million iprd impairment charge recognize bms lpa antagonist phase development treatment ipf writeoff require consider occurrence certain adverse event voluntary suspension study internal assessment indicate significantly low likelihood regulatory commercial success bms acquire bms acquisition amira pharmaceuticals inc note accrue liability december dollar million rebate return employee compensation benefit research development dividend royalty brand prescription drug fee restructure pension postretirement benefit litigation settlement accrue liability note equity common stock capital treasury stock excess par value accumulate retain noncontrolle dollar share million share par value stock comprehensive loss earning share cost interest balance january net earning comprehensive loss cash dividend stock compensation debt conversion distribution balance december net earning comprehensive loss cash dividend stock repurchase program stock compensation distribution balance december accounting change cumulative effecta adjust balance january net earnings comprehensive income cash dividend stock repurchase program stock compensation variable interest entity distribution balance december refer note accounting policy recently issue accounting standard additional information bms stock repurchase program authorize board director allow repurchase open market private transaction include plan establish accordance rule securities exchange act stock repurchase program expiration date suspend discontinue time treasury stock recognize cost reacquire share share issue treasury recognize utilize firstin firstout method bms repurchase share rule open market purchase accelerate share repurchase agreement bms complete accelerated share repurchase agreement repurchase approximately million share company common stock aggregate billion agreement fund combination debt cash component comprehensive incomeloss follow year end december dollar million pretax tax tax pretax tax tax pretax tax tax derivative qualify cash flow hedge unrealize gainslosse reclassify net earningsa derivative qualify cash flow hedge pension postretirement benefit actuarial gainslosse amortizationb settlementsc pension postretirement benefit availableforsale security unrealize gainslosse realize gainslossesc availableforsale security foreign currency translation total comprehensive incomeloss include cost product sell include cost product sell research development marketing sell administrative expense include income net accumulate balance relate component comprehensive loss net taxis follow december dollar million derivative qualify cash flow hedge pension postretirement benefit availableforsale security foreign currency translation accumulate comprehensive loss note pension postretirement benefit plan bms sponsor define benefit pension plan define contribution plan termination indemnity plan regular fulltime employee principal define benefit pension plan bristolmyers squibb retirement income plan cover employee represent approximately consolidated pension plan asset obligation future benefit relate service plan eliminate bms contribute minimum require erisa plan benefit base primarily participant year credit service final average compensation plan asset consist principally equity fixedincome security net periodic benefit costcredit define benefit pension plan include dollar million service cost benefit earn year interest cost project benefit obligation expect return plan asset amortization prior service credit amortization net actuarial loss curtailment settlement special termination benefit net periodic benefit costcredit pension settlement charge recognize determine annual lump sum payment exceed annual interest service cost certain pension plan include primary pension plan change define benefit pension plan obligation asset fund status amount recognize consolidated balance sheet follow dollar million benefit obligation begin year service costbenefit earn year interest cost settlement actuarial gainslosse benefit pay foreign currency benefit obligation end year fair value plan asset begin year actual return plan asset employer contribution settlement benefit pay foreign currency fair value plan asset end year fund status assetsliabilitie recognize asset accrue liability pension liability fund status recognize accumulate comprehensive loss net actuarial loss prior service credit total accumulate benefit obligation define benefit pension plan billion billion december respectively additional information relate pension plan follow dollar million pension plan project benefit obligation excess plan asset project benefit obligation fair value plan asset pension plan accumulate benefit obligation excess plan asset accumulate benefit obligation fair value plan asset actuarial assumption weightedaverage assumption determine define benefit pension plan obligation december follow discount rate rate compensation increase weightedaverage actuarial assumption determine define benefit pension plan net periodic benefit creditcost year end december follow discount rate expect longterm return plan asset rate compensation increase yield high quality corporate bond match duration benefit obligation determine discount rate citi pension discount curve develop discount rate plan expect return plan asset determine expect rate return calculate value asset refer marketrelated value approximate fair value plan asset december difference assume actual return amortize marketrelated value straightline basis threeyear period factor consider develop expect return plan asset include longterm historical return input external advisor individual asset class return forecast develop base market condition example priceearning level yield longterm growth expectation expect longterm rate return weightedaverage target asset allocation individual asset class historical longterm actual annualize return pension plan follow year year year actuarial gain loss result change actuarial assumption change discount rate revise mortality rate difference assume actual experience difference actual expect return plan asset gain loss amortize life expectancy plan participant plan year expect remain service period plan extent exceed high marketrelated value project benefit obligation respective plan amortization net actuarial loss prior service credit expect approximately million periodic benefit cost credit include cost product sell research development marketing sell administrative expense curtailment settlement special termination benefit include expense postretirement benefit plan comprehensive medical group life benefit provide substantially retiree elect participate comprehensive medical group life plan less extent certain benefit nonus employee medical plan contributory contribution adjust periodically vary date retirement life insurance plan noncontributory plan asset consist principally equity fixedincome securities postretirement benefit plan obligation million million december respectively fair value plan asset million million december respectively weightedaverage discount rate determine benefit obligation december respectively net periodic benefit credit material plan asset fair value pension postretirement plan asset asset category december follow december december dollar million level level level total level level level total plan asset equity security equity fund fix income fund corporate debt security treasury agency security shortterm investment fund insurance contract cash cash equivalent plan asset subject leveling plan asset measure nav practical expedient equity fund venture capital limited partnership total plan asset measure nav practical expedient net plan asset investment valuation policy investment class follow level input utilize unadjusted quote price active market accessible measurement date identical asset liability fair value hierarchy provide high priority level input instrument include equity security equity fund fix income fund publicly trade national security exchange cash cash equivalent cash cash equivalent highly liquid investment original maturity month time purchase recognize cost approximate fair value pende trade sale purchase include cash cash equivalent final settlement level input utilize observable price similar instrument quote price identical similar instrument nonactive market observable input corroborate market datum substantially term asset liabilitie equity fund fix income fund shortterm investment fund classify level fair value hierarchy value net asset value share hold year end represent fair value corporate debt security treasury agency security classify level fair value hierarchy value utilize observable price similar instrument quote price identical similar instrument market active level unobservable input little market datum available insurance contract hold certain foreign pension plan carry contract value approximate estimate fair value base fair value underlie investment insurance company venture capital limited partnership investment typically redeemable distribution liquidation underlie asset significant unfunded commitment investment essentially liquidation expect occur remain investment practical expedient redeemable weekly monthly basis investment strategy maximize return maintain appropriate level risk provide sufficient liquidity benefit obligation plan expense target asset allocation public equity international global private equity longduration fix income maintain pension plan investment diversify major asset category approximately pension plan equity investment actively manage bms common stock represent plan asset december contribution estimate future benefit payment contribution pension plan million million million expect approximately million estimate annual future benefit payment include lump sum payment range approximately million million year aggregate billion subsequent year period saving plan principal define contribution plan bristolmyer squibb saving investment program contribution base employee contribution level company match expense attribute define contribution plan approximately million note employee stock benefit plan shareholder approve plan replace stock incentive plan plan provide million share authorize grant plus share outstanding award plan february expire forfeit cancel withhold satisfy tax withholding obligation december million share available award share issue treasury stock satisfy obligation plan executive officer key employee grant option purchase common stock market price date option grant option generally exercisable ratably year maximum term year plan provide grant stock appreciation right grantee surrender exercisable right receive common stock andor cash measure excess market price common stock option exercise price company grant stock option stock appreciation right restrict stock unit grant key employee subject restriction continuous employment generally vest occur ratably year period grant date stock unit right receive stock end specify vest period voting right market share unit grant executive vest condition continuous employment vest date payout factor share price award date payout factor share price vest date divide share price award date maximum share price payout factor calculate average closing price grant vest date trading day immediately precede grant vest date vest occur ratably year performance share unit grant executive year cycle grant target number unit subject adjustment number share issue performance share unit vest determine base achievement performance goal base company threeyear total shareholder return relative peer group company vest condition continuous employment occur anniversary grant date stockbase compensation expense award ultimately expect vest recognize vest period forfeiture estimate base historical experience time grant revise subsequent period actual forfeiture differ estimate information relate stockbase compensation benefit follow year end december dollar million restrict stock unit market share unit performance share unit total stockbase compensation expense income tax benefit stock option restrict stock unit market share unit performance share unit weight number weight number weight number weight number average average average average option exercise price nonveste grantdate nonveste grantdate nonveste grantdate share million outstanding share awards fair value award fair value award fair value balance january grant releasedexercised adjustment actual payout forfeitedcancele balance december vest expect vest restrict market performance dollar million stock unit share unit share unit unrecognize compensation cost expect weightedaverage period year compensation cost recognize amount million share datum weightedaverage grant date fair value share restrict stock unit market share unit performance share unit fair value award vest restricted stock unit market share unit performance share unit total intrinsic value stock option exercise fair value restrict stock unit market share unit performance share unit approximate close trading price bms common stock grant date adjust unit eligible accrue dividend addition fair value market share unit performance share unit consider probability satisfy payout factor total shareholder return respectively follow table summarize significant range outstanding exercisable option december option outstanding exercisable number weightedaverage weightedaverage aggregate outstanding exercisable remain contractual exercise price intrinsic value range exercise price million life year share million aggregate intrinsic value precede table represent total pretax intrinsic value base close stock price december note legal proceeding contingency company certain subsidiary involve lawsuit claim government investigation legal proceeding arise ordinary course business claim proceeding involve type party include government competitor customer supplier service provider licensee employee shareholder resolution matter develop long period time expectation change result new finding ruling appeal settlement arrangement company recognize accrual contingency probable liability incur loss reasonably estimate matter involve patent infringement antitrust security pricing sale marketing practice environmental commercial contractual right licensing obligation health safety matter consumer fraud employment matter product liability insurance coverage legal proceeding material company believe material describe company believe substantial defense matter assurance increase scope pende matter future lawsuit claim government investigation legal proceeding material note company unable assess outcome respective litigation able provide estimate range potential loss furthermore failure enforce patent right likely result substantial decrease respective product revenue generic competition intellectual property plavix australia previously disclose sanofi notify august genrx proprietary limited genrx obtain regulatory approval application clopidogrel bisulfate tablets australia genrx subsidiary apotex inc apotex change apotex august apotex file application federal court australia federal court seek revocation sanofis australian patent case nsd sanofi file counterclaims infringement seek injunction september federal court grant sanofis injunction subsidiary company subsequently add party proceeding february second company spirit pharmaceuticals pty ltd file revocation suit patent case consolidate apotex case trial occur april august federal court australia hold claim patent cover clopidogrel bisulfate hydrochloride hydrobromide taurocholate salt valid federal court hold process claim pharmaceutical composition claim claim direct clopidogrel pharmaceutically acceptable salt invalid company sanofi file notice appeal court federal court australia court appeal hold invalidity claim cover clopidogrel pharmaceutically acceptable salt process claim pharmaceutical composition claim stay federal court rule apotex file notice appeal appeal hold validity clopidogrel bisulfate hydrochloride hydrobromide taurocholate claim hearing appeal occur february september court hold claim patent invalid november company sanofi apply high court australia high court special leave appeal judgment court march high court deny company sanofis request hear appeal court decision case remand federal court proceeding relate damage seek apotex company apotex settle apotex case case dismiss australian government intervene matter seek maximum damage million aud million plus interest split company sanofi allege loss experience pay high price brand plavix period injunction place company sanofi dispute australian government entitle damage australian government claim pende trial conclude september company expect decision sprycel european union apotex actavis group ptc ehf generics limited mylan unnamed company file opposition epo seek revocation european patent patent cover dasatinib active ingredient sprycel patent schedule expire april exclude potential term extension january opposition division epo revoke patent company appeal epos decision epo board appeal february epo board appeal uphold opposition division decision revoke patent orphan drug exclusivity datum exclusivity sprycel expire november epo board appeal decision affect validity sprycel patent outside europe include different patent cover monohydrate form dasatinib use dasatinib treat cml additionally february epo board appeal reverse remand invalidity decision european patent claim use dasatinib treat cml epo opposition division revoke october company intend appropriate legal action protect sprycel experience decline european revenue event generic dasatinib product enter market antipd antibody patent opposition litigation september danafarber cancer institute danafarber file complaint massachusetts federal court seek correct inventorship relate patent direct method treat cancer pdl antibodie specifically danafarber seeking add scientist inventor patent october pfizer allow intervene case allege scientist identify danafarber employ company eventually acquire pfizer relevant period adverse decision litigation result monetary liability company decrease potential future licensing revenue patent eliquis patent litigation twentyfive generic company send company paragraphiv certification letter inform company file abbreviate new drug application anda seek approval generic version eliquis result eliquis patent list fda orange book challenge composition matter patent claim apixaban specifically formulation patent april company partner pfizer initiate patent lawsuit hatchwaxman act generic filer federal district court delaware west virginia august united states patent trademark office grant patent term restoration composition matter patent restore term eliquis composition matter patent company basis project loe february november company settle lawsuit anda filer february settlement affect company project loe eliquis pricing sale promotional practice litigation plavix state attorney general lawsuit company certain affiliate sanofi defendant consumer protection andor false advertising action bring state relate sale promotion plavix product liability litigation company party product liability lawsuit plaintiff case seek damage relief ground allege personal injury economic loss previously disclose addition lawsuit company face unfiled claim involve product plavix previously disclose company certain affiliate sanofi defendant number individual lawsuit state federal court claim personal injury damage allegedly sustain plavix claim involve injury plaintiff claim spouse andor beneficiary file state federal court state include california new jersey delaware new york february judicial panel multidistrict litigation grant company sanofis motion establish multidistrict litigation mdl coordinate federal pretrial proceeding plavix product liability relate case new jersey federal court follow united states supreme courts june reversal california supreme court decision hold california state court exercise personal jurisdiction claim noncalifornia resident outofstate resident plaintiff claim include spouse beneficiary previously pende california state court dismiss number california non resident plaintiff claim refile federal court company file summary judgment motion remain case law firm represent majority remain case represent court withdraw discontinue case resolution remain lawsuit expect material impact company byetta amylin subsidiary company lilly codefendant product liability litigation relate byetta date separate lawsuit pende behalf approximately active plaintiff include pende settlement include injury plaintiff claim spouse andor beneficiary court previously report company agree resolve certain claim claim process dismiss majority case bring individual allege personal injury sustain byetta primarily pancreatic cancer pancreatitis case claim alleged wrongful death majority case pende federal court san diego mdl coordinated proceeding california superior court los angeles jccp november defendant motion summary judgment base federal preemption grant mdl jccp plaintiffs mdl appeal court appeal ninth circuit november ninth circuit reverse mdl summary judgment order remand case proceeding jccp plaintiff appeal california court appeal appeal remain pende amylin product liability insurance cover substantial number claim involve byetta additional liability amylin respect byetta expect share company astrazeneca abilify company otsuka codefendant product liability litigation relate abilify plaintiff allege abilify cause engage compulsive gambling impulse control disorder case file state federal court additional case pende canada judicial panel multidistrict litigation consolidated federal court case pretrial purpose united states district court northern district florida mdl trial currently schedule place june eliquis company pfizer codefendant product liability litigation relate eliquis plaintiff assert claim include claim wrongful death result bleed allege cause use eliquis majority claim pende mdl united states district court southern district new york state court delaware january case pende court unite states pende canada case dismiss prejudice mdl plaintiff appeal dismiss case second circuit court appeal shareholder derivative litigation december shareholder derivative lawsuit file new york state court certain officer director company plaintiff allege thing breach fiduciary duty surround company previously disclose october civil settlement securities exchange commission allege foreign corrupt practice act violation china company agree payment approximately million disgorgement penalty interest october lawsuit dismiss company receive notice appeal dismiss lawsuit security litigation february company aware putative class action complaint joseph giugno bristolmyers squibb file district northern district california company company chief executive officer giovanni caforio company chief financial officer charle bancroft certain current executive company complaint allege violation security law company disclosure relate checkmate clinical trial lung cancer company intend defend vigorously litigation government investigation like pharmaceutical company company certain subsidiary subject extensive regulation national state local government agency country bms operate result company time time subject governmental inquiry investigation possible criminal charge substantial fine andor civil penalty result government investigation environmental proceeding previously report company party environmental proceeding matter responsible state federal foreign law include cercla certain cost investigate andor remediate contamination result past industrial activity company current site waste disposal reprocess facility operate party cercla matter respect cercla matter company responsible state federal foreign law company typically estimate potential cost base information obtain environmental protection agency counterpart state foreign agency andor study prepare independent consultant include total estimate cost site expect costshare potentially responsible party company accrue liability probable reasonably estimable company estimate share future cost site million december represent sum good estimate good estimate reasonably estimate minimal probable range cost take account potential recovery party include estimate cost additional probable loss associate previously disclose north brunswick township high school remediation site note select quarterly financial datum unaudite dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earningsloss net earningsloss attributable noncontrolle interest bms earningsloss share basica earningsloss share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity dollar million share datum quarter second quarter quarter fourth quarter year total revenue gross margin net earning net earning attributable noncontrolle interest bms earning share basica earning share diluteda cash dividend declare common share cash cash equivalent marketable securitiesb total asset longterm debtc equity earning share quarter add amount year period compute discrete basis marketable security include current noncurrent asset longterm debt include current portion follow specify item affect comparability result second fourth dollar million quarter quarter quarter quarter year cost product solda marketing sell administrative license asset acquisition charge iprd impairment site exit cost research development provision restructure litigation settlement divestiture gain royalty license income pension charge loss debt redemption income net increasedecrease pretax income income taxis item income taxis attribute tax reform income taxis increasedecrease net earning noncontrolle interest increasedecrease net earning diluted nongaap eps calculation second fourth dollar million quarter quarter quarter quarter year cost product solda license asset acquisition charge iprd impairment site exit cost research development provision restructure litigation settlement divestiture gain royalty license income pension charge intangible asset impairment income net increasedecrease pretax income income taxis increasedecrease net earning specify item cost product sell accelerate depreciation asset impairment shutdown cost report independent register public accounting firm shareholder board director bristolmyers squibb company opinion financial statement audit accompany consolidated balance sheet bristolmyer squibb company subsidiary company december relate consolidated statement earning comprehensive income cash flow year period end december relate note collectively refer financial statement opinion financial statement present fairly material respect financial position company december result operation cash flow year period end december conformity accounting principle generally accept united states america audit accordance standard public company accounting oversight board united states pcaob company internal control financial reporting december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission report date february express unqualified opinion company internal control financial reporting basis opinion financial statement responsibility company management responsibility express opinion company financial statement base audits public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audits accordance standard pcaob standard require plan perform audit obtain reasonable assurance financial statement free material misstatement error fraud audits include perform procedure assess risk material misstatement financial statement error fraud perform procedure respond risk procedure include examine test basis evidence amount disclosure financial statement audits include evaluate accounting principle significant estimate management evaluate overall presentation financial statement believe audits provide reasonable basis opinion deloitte touche llp parsippany new jersey february serve company auditor item change disagreement accountant account financial disclosure item control procedure evaluation disclosure control procedure december management carry evaluation supervision participation chief executive officer chief financial officer effectiveness design operation disclosure control procedure term define exchange act rule base evaluation management conclude december disclosure control procedure effective management report internal control financial reporting management responsible establish maintain adequate internal control financial reporting supervision participation management include chief executive officer chief financial officer management assess effectiveness internal control financial reporting december base framework internal controlintegrate framework issue committee sponsor organization treadway commission base assessment management conclude company internal control financial reporting effective december provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance united states generally accept accounting principle inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp independent register public accounting firm audit company financial statement include report issue report effectiveness company internal control financial reporting december include change internal control financial reporting change company internal control financial reporting quarter end december materially affect reasonable likely materially affect company internal control financial reporting item information report independent register public accounting firm shareholder board director bristolmyers squibb company opinion internal control financial reporting audit internal control financial reporting bristolmyer squibb subsidiary company december base criterion establish internal control integrate framework issue committee sponsor organization treadway commission coso opinion company maintain material respect effective internal control financial reporting december base criterion establish internal control integrate framework issue coso audit accordance standard public company accounting oversight board united states pcaob consolidate financial statement year end december company report date february express unqualified opinion consolidated financial statement basis opinion company management responsible maintain effective internal control financial reporting assessment effectiveness internal control financial reporting include accompany management report internal control financial reporting responsibility express opinion company internal control financial reporting base audit public accounting firm register pcaob require independent respect company accordance federal security law applicable rule regulations securities exchange commission pcaob conduct audit accordance standard pcaob standard require plan perform audit obtain reasonable assurance effective internal control financial reporting maintain material respect audit include obtain understand internal control financial reporting assess risk material weakness exist test evaluate design operating effectiveness internal control base assess risk perform procedure consider necessary circumstance believe audit provide reasonable basis opinion definition limitation internal control financial reporting company internal control financial reporting process design provide reasonable assurance reliability financial reporting preparation financial statement external purpose accordance generally accept accounting principle companys internal control financial reporting include policy procedure pertain maintenance record reasonable detail accurately fairly reflect transaction disposition asset company provide reasonable assurance transaction record necessary permit preparation financial statement accordance generally accept accounting principle receipt expenditure company accordance authorization management director company provide reasonable assurance prevention timely detection unauthorized acquisition use disposition company asset material effect financial statement inherent limitation internal control financial reporting prevent detect misstatement projection evaluation effectiveness future period subject risk control inadequate change condition degree compliance policy procedure deteriorate deloitte touche llp parsippany new jersey february iii item director executive officer registrant reference proxy statement file march respect director registrant incorporate reference hereof response information require item information require item respect executive officer registrant include reliance general instruction instruction item regulation item executive compensation reference proxy statement file march respect executive compensation incorporate reference hereof response information require item item security ownership certain beneficial owner management relate stockholder matter reference proxy statement file march respect security ownership certain beneficial owner management incorporate reference hereof response information require item item certain relationship relate transaction reference proxy statement file march respect certain relationship relate transaction incorporate reference hereof response information require item item auditor fee reference proxy statement file march respect auditor fee incorporate reference hereof response information require item item